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ABSTRACT		
	Acute	promyelocytic	leukemia	(APL)	is	a	cytogenetically	distinct	subtype	of	acute	myeloid	leukemia,	characterized	by	the	chromosomal	translocation	t(15;17)	that	involves	the	retinoic	acid	receptor	(RAR)	gene	and	leads	to	the	production	of	the	fusion	 protein	 PML-RARα.	 In	 the	 past	 it	 has	 been	 successfully	 treated	with	 all-trans	 retinoic	 acid	 at	 high	 doses	 to	 differentiate	 the	 leukemic	 blast.	 The	 fusion	protein	indeed	retains	the	capability	to	binds	DNA	with	an	even	stronger	affinity	and	 recruits	 repressive	 co-factors,	making	 the	 cells	 insensitive	 to	 physiological	concentrations	of	retinoic	acid.		In	 the	 last	 few	 years,	 also	 the	 lysine-specific	 demethylase	 (LSD1)	 protein	 has	emerged	as	important	target	for	the	epigenetic	therapy	of	cancer.		We	found	that	both	pharmacological	inhibition	and	knock	down	of	LSD1	are	able	to	 sensitize	 NB4	 cells	 -	 a	 cells	 line	 derived	 from	 an	 APL	 patient	 -	 to	 lower	(physiological)	 doses	 of	 retinoic	 acid	 (RA)	 causing	 growth	 arrest	 and	differentiation	without	degradation	of	the	fusion	protein.	In	order	to	elucidate	the	role	of	LSD1	in	this	mechanism,	we	characterized	the	LSD1	genomic	distribution	in	acute	myeloid	leukemia	by	ChIP-seq	experiment	and	performed	RNA-seq	and	ChIP-seq	for	H3K4me1/me2/me3	and	H3K27ac	in	all	the	four	treatments	(DMSO	as	 control,	RA	 low,	RA	high,	 LSD1	 inhibition	and	 cotreatment	of	LSD1	 inhibitor	and	RA	low).			Results	 of	 RNA-seq	 analyses	 show	 significant	 changes	 in	 gene	 expression	 only	after	 co-treatment	 (RAlow	 +	 LSD1i)	 and	 RA	 high,	 in	 line	 with	 experimental	
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evidence	of	phenotype.	Moreover,	 in	addition	to	an	high	overlap	between	genes	expressed	in	both	co-treatment	and	RAhigh,	we	observe	a	significative	number	of	cotreatment-specific	 expressed	 genes	 that	 suggest	 a	 putative	 synergistic	 and	stronger	 effect	 of	 the	 cotreatment	 compare	 to	 the	 retinoic	 acid	 high	 alone.	 In	parallel,	 the	 data	 on	 histone	 modifications	 obtained	 through	 ChIP-seq	experiments	 show	 a	 significant	 increase	 of	 the	 di-metylation	 of	 H3K4	 after	treatment	 with	 inhibitor.	 This	 mainly	 occurs	 in	 regions	 marked	 with	 peaks	 of	LSD1	 and	 associated	 with	 genes	 involved	 in	 cell	 differentiation	 (genes	 over-expressed	 in	 co-treatment,	 but	 not	 in	 other	 single	 treatments).	 In	 the	 same	regions	 we	 observe	 the	 presence	 of	 H3K27	 acetylation	 after	 treatment	 with	retinoic	acid	but	not	after	LSD1	inhibition.	Only	after	treatment	with	both	drugs	the	 regions	 acquire	 the	 two	 histone	 marks,	 and	 we	 can	 observe	 an	 effective	phenotype	 of	 differentiation,	 correlating	 with	 the	 observed	 change	 in	 gene	expression.	An	hypothesis	might	be	 that	 there	 are	 regulatory	 regions	 linked	by	LSD1,	 which	 undergo	 a	 kind	 of	 “pre-mark”	 in	 histone	 modifications	 after	treatment	 with	 the	 inhibitor	 (gain	 of	 H3K4me2)	 or	 with	 retinoic	 acid	 (gain	 of	H3K27ac),	 which	 is	 necessary	 but	 not	 sufficient	 to	 determine	 a	 change	 in	expression,	 found	only	after	 co-treatment	 in	 the	 simultaneous	presence	of	both	epigenetic	modifications.	Overall	the	combination	of	the	LSD1	inhibition	and	RA	low	bypasses	the	block	of	PML-RAR	fusion	protein	activating	a	different	pathway	of	genes	compared	to	RA	high	with	stronger	effects	on	the	differentiation	of	the	cells.		Taken	together	our	results	contribute	to	understand	the	role	of	LSD1	in	the	RA-induced	differentiation	of	 leukemic	cells,	 suggest	new	therapeutic	 strategies	 for	the	 intervention	 in	 APL	 and	 potentially	 other	 leukemias,	 and	 highlight	 the	
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importance	 of	 combination	 therapies	 as	 new	 potent	 weapon	 in	 the	 cancer	treatments.			
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INTRODUCTION	
	
EPIGENETICS	
Epigenetics	is	defined	as	heritable	cell	traits	that	are	not	linked	to	changes	in	the	DNA	sequence	and	comprise	the	mechanism	by	which	the	chromatin	associated	proteins	 and	 post-translational	 modification	 of	 histone	 (PTMs)	 regulate	transcription.	It	is	well	known	that	all	the	cells	within	a	human	body	contain	the	same	DNA	sequences,	and	the	differentiation	of	all	these	cells	and	the	acquiring	of	distinct	 functions	 and	morphologies	 are	 due	 to	 epigenetic	 changes	 and	 its	 fine	regulation.	Thus	epigenetics	doesn’t	 involve	change	of	 the	sequence	of	 the	DNA	but	most	of	all	of	its	spatial	organization;	epigenetic	regulators	and	transcription	factors	 organize	 the	 genome	 into	 accessible	 or	 not	 accessible	 regions,	 which	determine	the	correct	activation	of	different	transcriptional	program	in	each	cell	type.	 The	 identity	 of	 each	 cells,	 determined	 by	 the	 expression	 of	 unique	 gene	patterns,	 must	 be	 remembered	 and	 passed	 to	 the	 daughter	 cells	 through	epigenetic	mechanisms.	Thus	epigenetic	is	essential	for	the	correct	maintaining	of	cell	 identity	 and	 is	 determinant	 for	 many	 fundamental	 process	 such	 as	proliferation,	 development,	 differentiation	 and	 genome	 integrity.	 These	regulations	 can	be	mediated	 through	 several	mechanism	 like	DNA	methylation,	ATP-dependent	nucleosome	remodeling,	replacement	of	canonical	histones	with	histone	 variants,	 post–translational	modification	 of	 histone	 (PTMs),	 non-coding	RNA	(ncRNAs).	Since	each	cell	type	has	its	unique	epigenome,	complex	organisms	have	multiple	epigenomes,	depending	on	the	tissue	type	and	development	stage.	
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Because	 of	 the	 key	 role	 of	 epigenetic	 mechanism	 in	 the	 control	 of	 several	biological	processes,	it	is	not	surprising	that	chromatin	alteration	may	lead	to	the	onset	 and	 progression	 of	 many	 diseases,	 first	 of	 all	 cancer.	 Unlike	 genetic	alteration,	 epigenetic	 alterations	 are	 generally	 reversible	 and	 for	 this	 reason	drugs	 against	 epigenetic	 target	 (epi.drugs)	 are	 considered	 as	 a	 new	 and	promising	field	for	cancer	therapy,	with	already	some	compounds	approved.			
CHROMATIN	STRUCTURE	AND	COMPONENT	
Chromatin	structure	can	be	viewed	as	a	series	of	superimposed	layers:	at	the	root	there	 is	 the	 DNA	 sequence	 and	 its	 direct	 chemical	 modification	 by	 cytosine	methylation;	 the	 DNA	 is	 then	 folded	 into	 nucleosome,	 composed	 by	 147	 bp	 of	DNA	 wrapped	 around	 the	 histone	 octamer,	 formed	 by	 a	 tetramer	 of	 H3-H4	histone	 and	 a	 couple	 of	 H2A-H2B	 histone	 dimers.	 The	 primary	 structure	 of	chromatin	is	represented	by	the	assembly	of	core	nucleosomes	with	the	fragment	of	DNA	linker	(so	called	“beads	on	a	string”),	while	the	presence	of	the	histone	H1	which	 binds	 the	 DNA	 linker,	 leads	 the	 structure	 to	 achieve	 a	 higher	 level	 of	compaction,	called	“30nm	fiber”.		The	degree	of	chromatin	wrapping,	specific	for	cell	 type	 and	 differential	 stage,	 could	 be	 divided	 in	 two	 main	 subtypes	 or	environments:	 euchromatin	 and	 heterochromatin.	 Both	 the	 environment	 are	enriched	 and	 also	 depleted	 of	 certain	 characteristic	 histone	 modification,	 with	regions	 of	 demarcation	 between	 heterochromatin	 and	 euchromatin.	 These	boundary	elements	are	enriched	of	specific	factors	such	as	CTCF,	that	play	a	role	in	 the	 maintaining	 of	 the	 boundary,	 H3K9me1	 and	 the	 histone	 variant	 H2A.Z,	while	 are	 depleted	 of	 histone	 acetylation.	 Euchromatin	 represent	 regions	accessible	 and	 generally	 active	 transcribed	 while	 heterochromatin	 includes	
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highly	 condensed	 regions	 with	 genes	 transcriptionally	 repressed,	 and	 with	mainly	 repetitive	 DNA	 sequences.	 In	 addiction	 to	 these	 well-known	 structures	three-dimensional	models	of	chromatin	are	now	reached	an	increased	precision	and	suggested	that	there	are	additional	sophisticated	level	of	genome	regulation	through	ulterior	order	of	organization	and	nuclear	compartmentalization.		The	 chromatin	 structure	 and	 condensed	 level	 are	 fining	 regulated	 and	 highly	dynamic	 and	 are	 due	 to	 the	 combined	 action	 of	 DNA	 methylation,	 histone	modification	and	chromatin	remodeling.	The	wide	range	of	histone	modification	occurs	 not	 only	 at	 the	 N-terminal	 tails,	 including	 acethylation,	 methylation,	phosphorylation,	 ubiquination,	 SUMOylation,	 crotonylation	 and	 others	 (Zentner	and	Henikoff,	 2013),	 	 but	 also	 in	 the	 core	of	 the	histones	and	 in	 the	C-terminal	regions	(Bannister	and	Kouzarides,	2011).		The	enzyme	responsible	 for	the	 fine	regulation	of	all	 these	histone	modification	can	be	divided	in	“writers”,	the	enzyme	responsible	for	the	addition	of	chemical	groups	 on	 eithers	 histone	 tails	 or	DNA	 itself,	while	 the	 proteins	 that	 recognize	these	specific	epigenetic	marks	are	called	“readers”.	Then,	since	all	the	epigenetic	modifications	 are	 not	 permanent,	 another	 class	 of	 enzyme	 called	 “erasers”	 can	remove	them.				
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Figure	 intro	 1.	 	 Epigenetic	 regulation	 is	 a	dynamic	process:	 epigenetic	writers	lay	down	marks	on	amino	acid	residues	on	 the	histone	 tails,	epigenetic	 readers	recognize	and	bind	 these	marks;	 epigenetic	 erasers	 catalyze	 the	 removal	of	 the	histone	marks.	All	 together	 these	 addictions	or	 removal,	 and	 the	 recognition	of	the	 histone	 marks	 determine	 a	 complex	 histone	 code	 that	 regulates	 various	processes	 including	 transcription,	 replication	 and	 repair	 (Falkenberg	 and	Johnstone,	2014).			 These	 mechanisms	 act	 in	 a	 coordinated	 manner	 with	 one	 another	 and,	 in	particular,	 the	 existence	 of	 a	 "histone	 code"	 or	 "epigenetic	 code"	 has	 been	proposed,	 according	 to	 which	 each	 histone	 modifications	 are	 recognized	 by	specific	 domains,	 part	 of	 the	 remodeling	 complexes	 or	 of	 transcription	 factors.	(Bird	A.,	2001;	Nakayama	et	al.,	2001).			
DNA	methylation		DNA	methylation	 represents	 the	most	 characterized	 epigenetic	modification;	 it	has	been	described	in	several	organisms	(Goldberg	et	al.,	2007)	and	is	involved	in	
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many	 different	 cellular	 functions	 including	 gametogenesis	 embryogenesis,	imprinting,	chromosome	X	inactivation	and	transcriptional	control	(Bird,	2002).	In	mammals	DNA	methylation	has	a	peculiar	distribution,	with	CpGs	dinucleotide	preferentially	methylated	 and	usually	 clustered	 in	CpGs	 rich	 regions	defined	as	CpG	islands.	These	regions	are	distributed	generally	around	promoters	and	first	exon,	 in	 the	 unmethylated	 status	 the	 genes	 associated	 are	 prone	 to	 be	transcriptionally	 activated,	 while	 on	 the	 contrary	 the	 methylation	 of	 the	 CpG	islands	 is	strongly	associate	with	silencing	of	 the	corresponding	genes	(Esteller,	2007).	 	The	enzymes	responsible	for	the	methylation	of	 	DNA	strands	are	called	DNA	 methyltransferases	 (DNMTs)	 and	 in	 mammals	 three	 different	 classes,	DNMT1,	DNMT3a,	DNMT3b	regulate	the	methylation	levels.	DNMT1	regulates	the	maintenance	of	the	methylated	status	by	recognizing	hemimethylated	DNA,	while	DNMT3a	and	DNMT3b	are	more	 considered	 as	 the	de	novo	methyltransferases	(Okano	et	al.,	1999)	and	their	activities	are	mostly	confined	to	the	early	stages	of	development,	where	they	regulate	the	proper	DNA	methylation	status	(Meissner	et	 al,	 2008).	 	 The	 differentiation	 process	 is	 the	 mainly	 affected	 by	 DNA	methylation,	 which	 in	 fact	 is	 higher	 in	 differentiated	 cells	 respect	 stem	 cells.	Moreover	the	genes	mainly	subjected	to	DNA	methylation	are	those	 involved	 in	the	manteinance	of	pluripotency	(Mohn	et	al.,	2008).		
	
Histone	modifications	and	cross-talk	Among	 the	 histone	 tails	 lysine	 and	 arginine	 residues	 are	 the	 main	 sites	 of	modification	 that	 principally	 includes	 acetylation	 and	 methylation.	 While	acetylation	 of	 the	 lysine	 abolishes	 the	 positive	 charge	 of	 the	 amino	 acid	 and	eliminates	in	this	way	the	electrostatic	bond	between	histones	and	DNA	allowing	
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euchromatin	 formation,	 methylation	 of	 lysine	 and	 arginine	 does	 not	 alter	 the	charge	(Copeland	et	al.,	2009).	There	are	numerous	chromatin-associated	factors	that	have	been	shown	to	recognize	and	interact	with	modified	histones	through	many	distinct	domains.	Lysine	methylation	is	the	histone	modifications	with	the	major	 number	 of	 recognizing	 domains,	 reflecting	 the	 modification’s	 relative	importance.	Interestingly	the	histone	modifications	not	only	are	recognized	from	specific	domains,	 recruiting	 cofactors	and	create	 in	 this	way	an	 interaction,	but	they	can	also	disrupt	the	interactions	between	histone	and	chromatin	factors.	For	example,	the	presence	of	H3K4me3	can	prevent	the	binding	of	NuRD	complex	at	the	 H3	 N-terminal	 tail,	 consistent	 with	 the	 fact	 that	 NuRD	 is	 a	 transcriptional	repressor,	while	H3K4me3	 is	a	marker	of	active	 transcription.	 (Zegerman	et	al.,	2002)	
	
Figure	 intro	 2.	 Examples	 of	 proteins	 and	 domain	 that	 specifically	 bind	 to	modified	histone	(Bannister	and	Kouzarides,	2011)		The	 large	 number	 of	 possible	 chromatin	 modifications	 and	 their	 recognition	provide	a	precise	and	tight	control	of	chromatin	structure.	 In	addiction	to	these	
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regulations	 there	 is	an	additional	 level	of	 complexity	and	regulation,	due	 to	 the	cross-talk	among	the	different	modifications.	These	cross-talk	can	occur	through	multiple	mechanism	(Kouzarides,	2007):		
• Competitive	 antagonism	 could	 be	 among	 modifications	 that	 occur	 at	 the	same	site;	
• one	modification	may	be	dependent	upon	another	(Lee	et	al.,	2007;	Kim	et	al.,	2009);	
• adjacent	 modifications	 can	 disrupt	 the	 binding	 of	 another	 modification	(Fischle	et	al.,	2005);	
• the	 activity	 of	 an	 enzyme	 may	 be	 affected	 by	 the	 modification	 of	 its	substrate	(Nelson	et	al.,	2006);	
• two	modifications	can	cooperate	in	order	to	recruit	specific	factors.		 Moreover,	 there	may	 be	 also	 interactions	 among	DNA	methylation	 and	 histone	modifications.	These	interactions	could	be	cooperative	but	also	inhibitive,	as	for	the	KDM2A	which	binds	nucleosomes	with	H3K9me3	only	when	the	DNA	is	not	methylated	(Bartke	et	al.,	2010).				
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Figure	 intro	 3.Histone	 modification	 cross-talk:	 the	 histone	 modifications	 can	affect	the	other	adjacent	or	distant	modification	in	a	positive	or	negative	manner.	(positive	 effects	 are	 indicated	 by	 an	 arrowhead	 while	 negative	 effects	 are	indicated	by	a	flat	head	(Bannister	and	Kouzarides,	2011).	
	
Histone	acetylation:	Lysine	acetyltransferases	and	deacetylases		Histone	 acetylation,	 first	 reported	 in	 1964	 by	 Allfrey	 and	 colleagues,	 is	 highly	dynamic	histone	modification	regulated	by	the	opposite	action	of	two	families	of	enzymes:	histone	acetylation	(HATs)	and	histone	deacetylation	(HDACs)	(Allfrey	et	al.,	1964).	The	histone	acetylases	utilize	acetyl	CoA	as	cofactor	and	catalyze	the	transfer	 of	 the	 acetyl	 group	 to	 the	 ε-amino	 group	 of	 lysine	 side	 chains.	 This	addiction	 neutralizes	 the	 lysine’s	 positive	 charge,	 weakening	 the	 interactions	between	histones	and	DNA.	HATs	can	be	divided	in	two	major	classes:type-A	and	type-B.	Type-B	are	predominantly	cytoplasmatic	and	acetylates	free	histones	not	already	deposited	into	chromatin,	 in	particular	histones	H4	at	K5	and	K12.	This	acetylation	 is	 important	 for	 the	 correct	 deposition	 of	 the	 histones	 (Parthun,	2007).	 The	 type-A	 comprises	 three	 more	 classes	 of	 HDAC:	 GNAT,	 MYST	 and	CBP/p300	(Hodawadekar	and	Marmorstein,	2007).	The	enzymes	of	these	classes	
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function	 as	 coactivators	 and	 are	 often	 associated	 with	 large	 multiprotein	complexes	(Yang	and	Seto,	2007).	The	effects	of	the	HDAC	are	opposite	to	HATs,	reversing	the	histone	acetylation	and	restore	the	positive	charge	of	the	histones,	stabilizing	 the	 chromatin	 architecture	 and	 acting	 as	 transcriptional	 repressor.	There	are	four	classes	of	HDAC:	class	I	proteins	are	homologous	of	the	yeast	Rpd3	and	localize	into	the	nucleus;	class	II	can	be	further	divided	into	two	classes,	class	III	 proteins	 are	 homologous	 of	 the	 yeast	 Sirt2	 and	 differ	 structurally	 from	 the	other	 classes,	 requiring	 NAD+	 as	 cofactors,	 class	 IV	 contains	 singe	 HDAC	 with	catalytic	 domain	 shared	 with	 class	 I/II.	 All	 the	 HDAC	 are	 typically	 present	 in	multiple	distinct	complexes,	also	often	with	other	members	of	HDAC	family.			
	
Histone	methylation:	Lysine	methyltranferases		The	enzymatic	methylation	of	histone	is	performed	by	lysine	methyltransferases	(KMTs)	and	arginine	methyltransferases	(PRMTs)	with	S-adenosyl-L-methionine	as	 the	methyl	 donor	 and	 can	 involve	 the	 transfer	 of	 up	 to	 three	methyl	 groups	resulting	in	mono-,	di-	or	thrimethylates	lysine	(Martin	and	Zhang,	2005)	or	the	transfer	 of	 one	 or	 two	 groups	 to	 the	 arginine	 (Greer	 and	 Shi,	 2012).	 Since	 the	same	modification	 could	 also	 lead	 to	 opposite	 activities,	 due	 to	 recruitment	 of	different	enzyme,	the	presence	of	a	histone	code	has	in	the	latest	years	shifted	to	a	“language”	which	 is	more	dependent	on	the	context.	Up	to	date	more	than	50	lysine	human	methyltransferases	(KMTs)	have	been	reported	and	these	enzymes	are	 characterized	 by	 the	 high	 selectivity	 concerning	 the	 histone	 lysine	 residue	target.	Several	residues	undergo	methylation:	H3K4,	H3K9	and	H3K27	among	the	others.	The	methyltransferases	are	divided	in	three	different	families:	one	acts	on	arginine	 (PRMTs	 family)	 and	 two	 on	 lysine	 the	 DOT-like	 proteins	 and	 the	 SET	
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domain-containing	 proteins.	 The	 SET	 proteins	 methylate	 lysines	 in	 histone	 as	well	 as	non-histone	substrates	and	can	be	divided	 into	 four	additional	 families:	SET1,	SET2,	SUV39	and	RIZ,	that	generally	act	in	multiprotein	complexes.		
	
LSD1	LYSINE-SPECIFIC	HISTONE	DEMETHYLASES	1A	
LSD1	 was	 the	 first	 experimental	 evidence	 of	 the	 existence	 of	 enzymatic	demethylation	and	was	first	isolated	as	partner	of	the	histone	deacthylase	HDAC2	in	HeLa	cells	(Tong	et	al,	1998).	Subsequent	analysis	 identified	LSD1	in	CoREST	transcription	repressor	complex	(Humphrey	et	al.,	2001;	You	et	al.,	2001;	Hakimi	et	 al.,	 2003),	 in	 association	 with	 NuRD	 complex	 (Wang	 et	 al.,	 2009)	 and	 with	several	 others	 factors.	 While	 some	 of	 the	 interactions	 of	 LSD1	 still	 remain	unclear,	 the	 incorporation	 of	 LSD1	 into	 protein	 complex	 such	 as	 CoREST	 and	NuRD	 is	 determinant	 for	 the	 LSD1	 ability	 to	 demethylate	 nucleosome;	 in	particular,	 LSD1	 requires	 association	 with	 RCOR1	 of	 the	 CoREST	 complex	 or	MTA2	of	 the	NuRD	complex	 (Shy	et	 al.,	 2005;	Lee	et	 al.,	 2005).	Moreover	 some	interactions,	like	LSD1:RCOR1,	also	prevent	LSD1	from	proteasomal	degradation,	while	 association	 with	 PHF21A	 binds	 un-methylated	 H3K4	 and	 leads	 to	 a	stabilization	 of	 the	 LSD1	 with	 chromatin,	 promoting	 the	 activity	 of	 LSD1	 as	 a	transcriptional	repressor.		The	 discover	 of	 LSD1	 opened	 the	 way	 for	 the	 isolation	 of	 an	 entire	 family	 of	demethylases,	 the	 JMJ	 proteins	 (Kooistra	 and	Helin,	 2012).	 Recently,	 in	 human	another	homolog	of	LSD1,	named	LSD2,	was	characterized,	which	exhibits	poor	sequence	identity	with	LSD1	(only	30%)	but	shared	similar	domains	(Fang	et	al,	2010).	The	structure	of	both	LSD	proteins	includes	a	N-terminal	SWIRM	domain	and	 an	 amino	 oxidase	 domain	 (AO)	 containing	 two	 binding	 sites,	 one	 forms	 a	
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non-covalent	FAD	binding	site	and	the	other	one	forms	the	substrate	binding	and	recognition	 site.	 These	 two	 pockets	 represent	 the	 catalytic	 domain	 of	 LSD	proteins,	 for	 which	 the	 enzymatic	 activity	 was	 first	 demonstrate	 by	 Shi	 and	collegues	in	2004.			
	
Figure	 intro	 4.	Histone	demethylases	 LSD1.	 LSD1	 is	 part	 of	 several	 chromatin	complexes,	including	nucleosome	remodelling		and	histone	deacethylase	(NuRD)	and	CoREST,	in	which	it	catalyse	the	demethylation	of	H3K4me2	and	H3K4me1.	(Helin	K.	and	Dhanak	D.,	2013)			The	protein	acts	as	demethylase	on	mono-	and	di-	methyl-lysine	4	of	histone	H3	(H3K4me1/me2)	 with	 production	 of	 formaldehyde	 and	 reduced	 form	 of	 FAD,	while	it	 is	not	able	to	demethylate	H3K4me3	(Shi	et	al.,	2005).	Nevertheless	the	substrate	 specificity	 of	 the	 protein	 is	 influenced	 by	 its	 association	 with	 other	cofactors:	 while	 generally	 LSD1	 demethylates	 H3K4me1/me2,	 leading	 to	transcriptional	repression,	when	it	interacts	with	the	androgen	receptor	(AR),	its	enzymatic	 activity	 switches	 to	 H3K9me1/me2	 with	 consequent	 transcriptional	activation	 (Metzger	 et	 al.,	 2005).	 Contrary	 to	 LSD2,	 LSD1	 contains	 a	 TOWER	domain	hairpin	 that	protrudes	 from	its	globular	portion	and	 is	essential	 for	 the	interaction	with	 other	 proteins	 like	 Co-REST.	 Interestingly,	 interaction	 of	 LSD1	
	 15	
with	 co-factors	 could	 affect	 the	 ability	 to	 demethylase	 and	 also	 the	 protein	stability	in	vivo	(Shi	et	al.,	2005).		LSD1	 is	 highly	 expressed	 in	many	 cancer	 type,	 including	 breast	 prostate,	 acute	myeloid	 leukemia,	 lung	 cancer	 and	 neuroblastoma	 (Lynch	 et	 al.,	 2012);	 is	 an	essential	gene	in	mammalian	biology	and	many	specific	roles	have	been	reported.	Germline	 murine	 knockout	 shows	 embryonic	 lethality	 before	 E7.5.	 Orkin	 and	collegues	 used	 in	 vitro	 experiement	 to	 uncover	 the	 role	 of	 LSD1	 in	 the	 multi-lineage	 hematopoietic	 differentiation	 (Saleque	 et	 al.,	 2007);	 role	 that	 has	 been	confirmed	 by	 conditional	 KO/KD	 murine	 system,	 highlightening	 a	 clear	involvement	 of	 LSD1	 in	 several	 steps	 of	 the	 physiological	 hematopoietic	differentiation	 	 (Sprussel	 et	 al.,	 2012;	 Kerenyi	 et	 al.,	 2013).	 	 Conditional	 KD	 of	LSD1	 leads	 to	 abnormal	 expansion	 of	 immature	 progenitors	 and	 consequent	impairment	 in	most	 lineage	 terminal	differentiation,	a	phenomenon	 that	can	be	reverted	 by	 restoring	 LSD1	 expression	 (Sprussel	 et	 al.,	 2012).	 Morover,	 and	consistent	with	these	findings,	the	complete	deletion	of	the	gene	in	hematopoietic	compartments	leads	to	alteration	of	HSC	self	renewal	and	impairment	of	terminal	granulocytic	and	erythroid	maturation.	Both	mRNA	and	LSD1	protein	are	highly	expressed	in	undifferentiated	human	embryonic	stem	cells,	while	the	expression	progressively	decreases	during	differentiation,	suggesting	a	significant	role	in	the	differentiation	through	maintenance	of	pluripotency	by	the	fine	control	of	H3K4	methylation	 at	 genes	 exhibiting	 bivalent	 domains	 (marked	 by	 both	H3K4me2/me3	and	H3K27me3)	such	as	FOXA2,	EOMES	and	BMP2	(Adamo	et	al.,	2011).		
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Pharmacological	inhibition	of	LSD1	and	potential	clinical	use		Given	 its	 enzymatic	 activity	 and	 the	 observation	 of	 high-level	 of	 expression	 of	LSD1	 in	many	malignancies	 in	 the	 last	 few	years	 there	 is	 a	 growing	 interest	 in	developing	potent	and	specific	pharmacologic	 inhibition	of	LSD1	(Amente	et	al.,	2013).	 	 In	 particular,	 in	 neuroblastoma	 LSD1	 is	 often	 found	 overexpressed	(Schulte	 et	 al.,	 2009)	 while	 the	 overexpression	 in	 prostate	 cancer	 serves	 as	 a	marker	 for	 cancer	 recurrence	 (Kahl	 et	 al.,	 2006)	 and	 poor	 prognosis	 in	 SCLC,	where	it	promotes	invasion	progression	and	proliferation	(Amente	et	al.,	2013).	On	the	contrary,	other	studies	have	proposed	LSD1	as	 tumor	suppressor.	Wang	and	colleagues	demonstrated	the	involvement	of	LSD1	in	breast	cancer	migration	and	the	down-regulation	of	the	protein	in	breast	carcinoma	(Wang	et	al.,	2009).		The	 involvement	 of	 LSD1	 in	 cellular	 differentiation	 has	 been	 demonstrated	 in	several	 studies	 (Wang	 et	 al.,	 2007;	 Musri	 et	 al.,	 2010)	 and	 its	 role	 in	hematopoietic	 differentiation,	 through	 the	 repression	 of	 GFI1	 targets,	 was	proposed	by	Saleque	and	colleagues	(Saleque	et	al.,	2007).		Tranylcypromine	 (TCP:	 trans-2-phen-ylcyclopropylamine),	 a	 non-selective	 and	irreversible	 monoamine	 oxidase	 inhibitor	 (MAOI),	 and	 approved	 drug	 for	 the	treatment	of	depression,	was	the	first	drug	reported	to	 inhibit	LSD1	through	an	inactivation	 mechanism	 involving	 covalent	 modification	 of	 the	 cofactor	 FAD.	Because	of	the	relative	lack	of	potency	and	specificity,	together	with	several	side	effects,	 many	 derivatives	 of	 tranylcypromine	 were	 subsequently	 developed.	Several	reversible	LSD1	inhibitors	have	been	reported	 in	the	 last	years,	most	of	which	 remain	 at	 an	 early	 phase	 of	 development	 but	 maintain	 the	 potential	 to	establish	a	novel	type	of	LSD1	inhibitor	with	alleviation	of	some	of	the	side	effects	reported	for	the	tranylcypromine	on	erythropoiesis.		
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The	tranylcypromine	 	derivative	inhibitor	GSK2879552	was	screened	in	a	panel	of	165	cell	lines	revealing	that	AML	and	SCLC	lines	are	particularly	sensitive.		In	vivo	 the	 drug	 effectively	 prevents	 growth	 of	 xenografted	 SCLC	 cell	 without	inducing	hematologic	 toxicities	and	showing	prolonged	survival	 (Mohammad	et	al.,	 2015).	 	 The	 inhibitor	 is	 currently	 undergoing	 evaluation	 in	 early	 phase	 of	clinical	 trial	 (phase	 I)	 for	patients	with	AML	or	 small	 cell	 lung	 cancer,	 together	with	 the	 Orizon	 compound	 ORY-1001,	 which	 is	 in	 phase	 I/II	 clinical	 trial	 for	patient	 with	 relapsed	 or	 refractory	 acute	 leukemia.	 Also	 the	 inhibitor	 OG86,		known	as	Compound	B,	is	effective	in	human	primary	APL	cells	and	cell	line,	with	promotion	of	differentiation	and	in	vivo	blocked	of	accumulation	of	blasts	in	the	blood	 and	 impaired	 the	 proliferative	 potential	 of	 AML	 cells	 but	 not	 normal	hematopoietic	 stem	 and	 progenitor	 cells	 (Harris	 et	 al.,	 2012).	 RN-1	 is	 another	tranylcypromine	 derivative	 inhibitor	 which	 is	 effective	 across	 a	 large	 panel	 of	AML	and	acute	lymphoblastic	leukemia	cell	lines,	with	increasing	effects	on	AML	cells	 harboring	 the	 t(8;21)	 and	 MLL-rearrangements.	 The	 inhibitor	 completely	stops	 the	 Kasumi-1	 xenograft	 growth	 at	 well-tolerated	 doses	 (McGrath	 et	 al.,	2016).		In	 AML	 LSD1	 inhibitors	 were	 tested	 also	 in	 combination	 therapies:	tranylcypromine	 or	 tranylcypromine	 derivatives	 have	 shown	 to	 increase	 the	effects	 with	 all-trans	 retinoic	 acid,	 potentiating	 differentiation	 and	 loss	 of	clonogenic	 potential	 (Binda	 et	 al.,	 2010;Schenk	 et	 al.,	 2012)	 while	 the	combination	 with	 HDAC	 inhibitor	 (using	 vorinostat	 and	 tranylcypromine)	 has	also	 shown	 a	 response	 in	 glioblastoma	 cell	 line	 and	 patient-derived	 xenograft	(Singh	 et	 al.,	 2015).	 Moreover	 synergistic	 effects	 have	 also	 been	 reported	between	RN-1	and	cytarabine	and	between	RN-1	and	EZH2	in	vivo	using	AML	cell	
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lines	 (McGrath	 et	 al.,	 2016).	 Because	 of	 the	 cross	 talks	 between	 histone	modification	 and	 the	 interaction	 with	 chromatin	 remodeling	 proteins,	combination	 of	 epi-inhibitors	 could	 represent	 an	 interesting	 approach	 for	 the	future	therapeutic	interventions.	Combination	of	drugs	that	altered	chromatin	or	DNA	 methylation	 status	 has	 already	 been	 tested	 with	 promising	 results	 and	synergistic	 reactivation	 of	 tumor-suppressor	 genes	 and	 enhanced	 anti-cancer	effect	 in	 several	 malignancies.	 The	 improvement	 of	 combination	 therapies	compared	 to	 single	 agent	 drugs	 could	 be	 the	 reduction	 of	 acquired	 resistances	and	the	limitation	of	the	side	effects	through	the	use	of	lower	dosages	of	one	or	both	the	drugs.		Despite	 the	 number	 of	 inhibitors	 and	 their	 effectiveness	 is	 greatly	 increased	 in	recent	 years,	 the	 mechanism	 of	 action	 of	 the	 inhibitors	 has	 not	 yet	 been	 fully	clarified	 and	 this	 is	 the	 purpose	 of	 this	 thesis,	 in	which	we	 analyze	 the	 role	 of	LSD1	 in	 the	 combined	 treatment	 of	 a	 novel	 LSD1	 inhibitor	 and	 retinoic	 acid,	proposing	a	mechanism	of	action	that	involves	changes	of	histone	modifications	in	regions	associated	to	the	protein	and	changes	in	gene	expression	profile.		
	
HISTONE	MODIFICATION	AND	TRANSCRIPTIONAL	REGULATION	
In	the	last	years	with	the	increasing	number	of	high	throughput	data	many	efforts	have	 been	 done	 that	 aim	 to	 integrate	 different	 data	 types,	 from	 histone	modification	to	transcriptional	data,	trying	to	develop	new	hypothesis	regarding	the	 regulatory	 functions	 of	 all	 these	 chromatin	 features.	 Integration	 of	 histone	modification	 maps	 with	 chromatin	 accessibility,	 nucleosome	 positioning,	transcription	 factors	 binding	 sites,	 RNA	 expression	 and	 genome	 annotation	 is	providing	 increasingly	 unified	 vision	 of	 chromatin	 structure	 and	 function.	
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Although	 there	 is	a	continuous	stream	of	new	discoveries,	 today	we	are	able	 to	characterize	 certain	 states	 of	 chromatin	 and	 their	 functions	by	 the	presence	 or	absence	 of	 chromatin	 remodeling	 complexes,	 histone	 modifications	 and	nucleosome	 structure.	 The	 possibility	 to	map	 histone	modifications	 at	 genomic	scale	 and	 to	 generate	 the	 expression	 information	 related	 to	 these	 regions	 had	lead	to	the	identification	of	chromatin	features	indicative	of	both	transcribed	or	repressed	genes	and	 to	a	comprehensive	picture	of	 the	epigenome	(Enrst	et	al.,	2011).	 The	 DNA	 methylation	 occurs	 throughout	 all	 the	 genome	 except	 for	functional	 regulatory	 regions,	 which	 includes	 promoter	 and	 enhancer.	 Large	heterochromatin	 domains	 are	 associated	 with	 the	 presence	 of	 H3K9me2	 and	H3K9me3	as	well	as	HP1	binding	while	euchromatic	domains	are	characterized	with	localized	signals	of	H3K4me	and	histone	variant	H2A.Z	and	H3.3	occurring	mainly	 at	 functional	 regions	 as	 promoters,	 enhancer	 and	 insulator.	 Promoter	regions,	corresponding	to	cis-regulatory	regions,	which	span	the	transcriptional	start	site	(TSS)	and	are	necessary	to	guide	the	transcription	activation,	could	be	active	and	marked	with	H3K4me3	or	repressed	and	associated	with	H3K27	and	H3K9	trimethylated	marks	(Barski	et	al.,	2007).	These	regions	are	also	depleted	from	nucleosome	as	evident	from	the	DNaseI	hypersensitivity.	Even	if	H3K27me3	and	H3K4me3	seem	to	be	alternatively	present	in	genome	regions,	they	coexist	in	the	early	development	at	genes	called	“bivalent”,	characterized	by	the	presence	of	both	the	marker	and	by	the	possibility	to	easily	switch	from	one	to	another.	While	the	 presence	 of	 both	 the	 markers	 determines	 the	 “poised”	 state,	 the	 loss	 of	H3K27me3	 and	 the	 acquisition	 of	 H3K4me3,	 or	 vice	 versa,	 determines	 the	respective	activation	or	repression	of	the	genes.	The	pattern	of	PTMs	associated	to	 enhancer	 is	 still	 not	 fully	 elucidate,	 although	 seems	 to	 include	 high	 levels	 of	
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H3K4me1	 and	 low	 levels	 of	 H3K4me3,	 together	 with	 p300	 association	(Heintzman	 et	 al.,	 2007).	Also	 enhancer	 could	be	 sub-divided	 in	 “poised”	when	presenting	H3K27me3,	or	“active”	when	associated	to	H3K27ac	(Rada-Iglesias	et	al.,	 2011).	 All	 these	 data	 support	 the	 hypothesis	 that	 all	 the	 chromatin	components	 are	 not	 independent	 elements	 but	 they	 instead	 can	 influence	 one	another	and	that	a	complex	interplay	is	necessary	for	a	fine	regulation	needed	by	the	 cell.	 It	 is	 not	 surprising	 that	 epigenetic	 alteration	 even	 at	 single	 gene	 level	could	predispose	to	disease,	including	cancer.			
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Figure intro 5. The interaction of DNA methylation and histone modification 
together with other  regulative factors such as small RNAs constitute the epigenome of 
the cells which regulates gene expression and allows cells to remember their identity. 
In general, chromatin is divided in euchromatin (more accessible regions, rich in 
expressed or poised genes) and heterochromatin (poorly accessible regions enriched in 
silenced genes). Heterochromatic regions are mainly associated to H3K9 methylation, 
while methylated form of lysine 4,27 and 36 of the histone are enriched in eurcromatin 
(Schones and Zhao, 2008). 	
	
	
	
	
EPIGENETIC	ALTERATION	IN	CANCER	
	Since	 the	 epigenetic	 machinery	 contributes	 to	 regulate	 most	 of	 the	 cellular	functions,	 it	 is	 not	 surprising	 that	 perturbation	 of	 the	 normal	 epigenome	 could	lead	 to	 improper	 activation	 or	 repression	 of	 several	 transcriptional	 pathways,	which	could	 impair	both	 initiation	and	progression	of	many	diseases,	 first	of	all	cancer.	 The	mechanisms	 by	which	 aberrant	 histone	modification	 profiles,	 DNA	methylation	or	dysregulated	activity	of	the	associate	enzyme	lead	to	cancer	onset	are	 at	 least	 two:	 	 the	 alteration	 of	 oncogene	 or	 oncosoppressor	 expression	 at	single	 genes	 level	 or	 the	 impairment	 of	 the	 organization	 of	more	wide	 regions	which	may	affect	genome	integrity	and/or	chromosome	segregation.		A	 global	 reduction	 of	 DNA	 methylation	 characterizes	 the	 cancer	 cell,	 together	with	 a	 specific	 acquisition	 of	 hypermetilation	 at	 the	 CpG	 islands	 of	 certain	promoter,	 such	 as	 VHL,	 p16,	 BRCA	 and	Rarβ,	 or	 genes	 involved	 in	DNA	 repair,	such	as	MGMT	(Esteller	and	Herman,	2002,	Kulis	and	Esteller,	2010).		Generally,	DNA	hypomethylation	often	occurs	at	repetitive	element,	impairing	the	chromosomal	 stability,	 or	 at	 specific	 oncogene	 promoters,	 while	 the	hypermethylation	is	observed	at	genes	with	oncosuppressive	functions,	involved	
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often	 in	DNA	 repair,	 cell	 cycle	 control	 and	 apoptosis	 and	probably	 causes	 their	silencing	(Nguyen	et	al.,	2001;	Sadikovic	et	al.,	2008).		In	 AML,	 recent	 genome-wide	 studies	 of	 methylation	 on	 344	 AML	 samples	revealed	 that	 AML	 samples	 could	 be	 divided	 in	 16	 subclasses	 according	 to	 the	methylation	 signature	 that	 are	 often	 associated	 to	 cytogenetic	 or	 molecular	characteristics	(Figueroa	et	al.,	2010),	suggesting	that	aberrant	DNA	methylation	is	very	specific	and	related	with	driving	genetic	lesion	(Akalin	et	al,	2012).		Histone	modifications	are	also	globally	altered	in	cancer	(Baylin	and	Jones,	2011;	Elsheikh	 et	 al.,	 2009).	 Fraga	 and	 colleagues	 recently	 demonstrated	 that	 global	loss	monoacetylation	at	lysine	16	of	histone	H4	and	trimethylation	at	lysine	20	of	histone	 H4	 is	 a	 common	 hallmark	 of	 human	 cancer	 cells	 (Fraga	 et	 al.,	 2005).	Moreover	 global	 histone	 acetylation	 has	 been	 suggested	 as	 independent	prognostic	factor	in	several	cancer	types	(Barlesi	et	al.,	2007;	Manuyakorn	et	al.,	2010;	Seligson	et	al.,	2005).		These	alteration	 in	 the	epigenetic	profile	are	due	 to	different	mechanism	which	include	direct	genetic	alteration	of	enzyme	responsible	for	the	deposition	or	the	removal	of	the	histone	modifications	(e.g.	the	translocation	of	the	mixed	lineage	leukemia	 MLL	 which	 is	 an	 histone	 methyltransferases),	 or	 alteration	 due	 to	abnormal	recruitment	of	histone	modifiers	(such	as	the	aberrant	recruitment	of	HDAC-cointaining	 complex	 and	 DNMTs	 on	 the	 target	 genes	 of	 RAR	 due	 to	 the	PML-RAR	alpha	(Minucci	and	Pelicci,	2006).		The	involvement	of	DNA	methylation	and	histone	modification	in	cancer	lead	in	the	 last	 year	 to	 the	approval	of	 the	 first	 two	drugs	 (azacitidine	and	decitabine)	inhibiting	 the	 DNA	 methyltransferases	 enzymes	 DNMT1	 and	 DNMT3	 and	
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currently	 used	 for	 the	 treatment	 of	 patients	 with	 myelodisplastic	 syndrome	(Kantarjian	et	al.,	2007;	Issa	and	Kantarjian,	2009).		Few	years	later	also	two	histone	deacetylases	inhibitors	(SAHA	and	romidepsin)	were	 approved	 for	 the	 treatment	 of	 refractory	 cutaneous	T-cell	 lymphoma	 and	others	are	 in	various	stages	of	development	(Mercurio	et	al.,	2010;	Nebbioso	et	al.,	2012).		Although	 the	 introduction	 of	 these	 epi-drugs,	 directly	 targeting	 epigenetic	regulators,	 has	 been	 a	 huge	 success	 for	 the	 field,	 the	 clinical	 results	 are	 not	satisfying	 as	 expected	 and	 a	 large	 numbers	 of	 scientific	 challenges	 still	 remain,	most	of	them	due	to	the	fact	that	the	exact	mechanism	of	actions	of	these	drugs	is	often	unknown	and	to	the	lack	of	specificity	of	the	compounds.	Moreover	the	lack	of	 reliable	 molecular	 biomarkers	 for	 the	 prediction	 of	 clinical	 resistance	 of	sensitivity	 is	 a	 serious	 drawback	 that	 preclude	 the	 correct	 stratification	 in	 the	clinical	 trials.	 Additional	 reasons	 are	 also	 the	 context-specific	 effects	 of	 the	epigenetic	 drugs	 that	 act	 in	 a	 different	 manner	 on	 the	 different	 tumor	 cell	subtype,	like	cancer	stem	cells	versus	the	bulk	of	the	tumor,	(Santoro	et	al.,	2013;	Shlush	et	al.,	2014)	and	the	use	of	these	epigenetic	drugs	as	single	agent	when	the	complexity	 of	 the	 epigenome	 alteration	 in	 cancer	 requires	 simultaneous	interference.		
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GENOME	 WIDE	 APPROACHES	 FOR	 THE	 STUDY	 OF	 CHROMATIN	
MODIFICATIONS	
	Since	the	discovery	of	the	role	of	DNA	and	its	structure	in	1953	one	of	the	biggest	challenge	 to	 scientists	 has	 been	 “cracking	 the	 code”	 and	 deciphering	 the	 DNA	sequencing	in	order	to	assign	them	the	functional	role	in	the	cell.	The	sequencing	was	 the	 first	 method	 through	 which	 scientists	 could	 actually	 sequenced	 the	genetic	 information	 and	 its	 mechanism	 (Sanger	 et	 al,	 1992).	 The	 Sanger	sequencing	 is	 based	 on	 the	 selective	 incorporation	 of	 chain-terminating	dideoxynucleotides	by	DNA	polymerase	during	in	vitro	DNA	replication.	Although	this	method	was	widely	used	as	sequencing	method	for	approximately	39	years	it	is	heavily	impaired	by	many	limitations	such	as	sequencing	speed,	scalability	and	laboratory	 protocols.	 The	 early	 years	 of	 2000	marked	 the	 turning	 point	 of	 the	sequencing	 techniques	 with	 the	 introduction	 of	 so-called	 Next	 Generation	Sequencing	(NGS)	(Marziali	et	al.,	2001)	that	introduced	a	completely	new	way	of	sequencing,	 able	 to	processes	millions	of	bases	 in	 the	 range	of	hours	with	high	precision	level.	The	technique	still	relied	on	the	incorporation	on	nucleotides	in	a	fragment	of	DNA	re-synthetized	 from	a	 template	strand	but,	 contrary	 to	Sanger	sequencing,	 all	 the	 NGS	 techniques	 rely	 on	 light	 emitted	 by	 the	 incorporates	nucleotides,	 each	 labeled	 with	 a	 specific	 fluorescent	 marker.	 Since	 the	 first	appearance	in	2004	many	new	platforms	have	been	released	with	an	exponential	decrease	 of	 time	 and	 cost	 for	 each	 experiment.	 The	 affordable	 price	 of	 the	technique,	 the	possibility	to	sequence	different	experiment	 in	the	same	run	and	to	adjust	the	coverage	and	average	length	of	the	reads	have	made	NGS	the	most	widely	used	technique	for	any	type	of	genome	wide	experiment,	a	type	of	analysis	which	in	recent	years	has	replaced	the	gene-centric	approach.		
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The	 high–throughput	methods	were	 then	 applied	 to	 any	 type	 of	 assay,	making	them	genome-wide.		Although	 chromatin	 immunoprecipitation	 has	 been	 used	 since	 1988,	 its	combination	 with	 next	 generation	 sequencing	 has	 provide	 a	 precise	 and	comprehensive	 views	 of	 transcription	 factors	 and	 histone	 modification	landscape,	 highlighting	 roles	 of	 chromatin	 structure	 across	 different	 genomic	features.		
	
Figure	 intro	6.	Histone	modifications	mark	functional	elements	at	 the	genome.	Schematic	 representation	 of	 promoters,	 gene	 bodies	 and	 boundary	 element.	Active	promoters	are	commonly	marked	by	H3K4me2,	H3K4me3,	acetylation	and	histone	 variant	 H2A.Z,	 while	 the	 transcribed	 genes	 body	 are	 marked	 by	H3K36me3	 and	 H3K79me2.	 Enhancers	 are	 relatively	 enriched	 for	 H3K4me1,	H3K4me2	 and	 H3K27ac	 and	 the	 histone	 acethyltransferase	 p300;	 repressed	regions	 may	 be	 located	 in	 large	 domain	 characterized	 by	 the	 presence	 of	H3K27me3	and	H3K9	me2	and/or	me3.	(Zhou	et	al,	2010)						The	development	of	the	next	generation	sequencing	has	brought	also	the	study	of	transcriptome	 to	 a	 whole	 other	 level,	 allowing	 the	 quantification	 of	 all	 the	transcripts	 present	 in	 the	 cell,	 and	 lead	 to	 enhancing	 understanding	 of	
	 26	
mechanism	behind	several	cell	process	and	human	disease.	By	retro-transcribing	RNA	 to	 cDNA	 the	 NGS	method	 could	 be	 used	 to	 study	 the	 transcriptome	with	times	and	cost	that	continue	to	decrease	since	the	first	usage	in	the	2007	(Emrich	et	al.,	2007).		
	
	
BIOINFORMATICS	WORKFLOW	
The	next	generation	sequencing	and	the	huge	shift	in	data	collection	and	analysis	have	 introduced	new	challenges	 from	computational	point	of	view	and	 the	NGS	era	 is	 characterized	 also	 from	 the	 constant	 needing	 of	 new	 bioinformatic	 tools	and	workflows	(Stein,	2011).	
	
ChIP-seq	The	 use	 of	 specific	 antibody	 against	 protein	 of	 interest	 or	 histone	modification	followed	 by	 high-throughput	 sequencing	 leads	 in	 the	 last	 years	 to	 genome	localization	 of	 thousand	 of	 transcription	 factors	 and	 histone	 modification.	 The	ChIP-seq	process	enriches	specific	DNA	sequences	cross-linked	to	the	protein	or	histone	 marks	 of	 interest	 that	 subsequently	 undergo	 sequencing.	 The	 reads	obtained	 from	 sequencing,	 after	 quality	 score,	 were	 aligned	 to	 the	 reference	genome.	 Only	 parts	 of	 the	 total	 amount	 of	 the	 reads	 of	 the	 experiment	will	 be	uniquely	mapped	and	the	percentage	of	the	these	uniquely	mapped	reads	varies	among	organisms;	for	human	above	70%	is	quite	normal,	whereas	less	than	50%	could	be	a	problem.	A	low-percentage	of	uniquely	mapped	reads	is	often	due	to	
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excessive	PCR	cycles	of	amplification,	inadequate	sequences	length	or	sequencing	platform	 problems.	 Nevertheless	 the	 use	 of	 NGS	 provides	 relatively	 high	resolution,	low	noise	and	higher	genomic	coverage	compared	to	ChIP-chip	assay	(ChIP	 followed	 by	microarray	 hybridization)	 and	 is	 nowadays	 the	widely	 used	approach	 to	 the	 study	 of	 genome-wide	 DNA-protein	 interaction,	 and	 mapping	histone	modification.		
	
Figure	 intro	 7.	 A	 ChIP-seq	 peaks	 	 overview	 (image	 adapted	 from	http://biocluster.ucr.edu/~rkaundal/workshops/R_feb2016/ChIPseq/ChIPseq.html)		 The	 most	 discussed	 part	 of	 the	 ChIP-seq	 analysis	 is	 the	 identification	 of	 true	“peaks”	 in	 the	 data,	 where	 a	 peak	 is	 a	 region	 enriched	 of	 mapped	 reads	 that	produce	a	pileup.	Most	of	the	time	the	ChIP-seq	was	performed	as	single-end	and	
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sequenced	from	their	5’	ends	only:	two	distinct	peaks	ere	generated,	one	for	each	strand	where	the	shift	between	the	two	peaks	represent	the	exact	binding	site	of	the	protein.	For	the	peakcalling	the	use	of	a	control	is	strictly	suggested,	and	the	possible	 controls	 used	 are	 (i)	 an	 input	 DNA	 sample,	 DNA	 cross-linked	 and	sonicated	 but	 non	 immunoprecipitated	 or	 (ii)	 an	 IgG	 “mock”	 ChIP,	 using	 an	antibody	that	will	non	bind	nuclear	proteins.	Once	identified	the	peaks	related	to	the	protein	of	 interest	or	 the	histone	mark,	 the	aim	 is	 to	associate	 the	ChIP-seq	peaks	to	functionally	relevant	regions	such	as	gene	promoters,	TSS	or	intergenic	regions.	 	 This	 step	 is	 called	 annotation	 and	 it	 is	 only	 the	 first	 part	 of	 all	 the	possible	downstream	analysis.			
	
Figure	intro	8.	A	typical	ChIP-seq	data	analysis	workflow	
	
RNA-seq	Typical	workflow	 for	RNA-seq	experiments	start	with	 isolation	and	purification	of	total	or	part	of	the	RNA	present	in	the	cells,	followed	with	fragmentation	and	
Experimental design & 
execution Sequencing & alignment Peak calling 
Annotation 
Motif discovery 
Visualization in  
genome browser 
Enriched regions 
Gene set analysis 
Integration with  
gene expression 
Differential profile 
analysis 
	 29	
creation	 of	 the	 libraries	 with	 cDNA	 synthesis.	 Once	 the	 cDNA	 has	 been	synthetized	 and	 sequencing	 adapters	 added	 the	 sample	 is	 almost	 ready	 to	undergo	sequencing	and	subsequent	bioinformatics	analysis.	The	analysis	starts	with	the	initial	filtering	of	the	sequencing	reads,	eliminating	reads	with	low	base	quality	 confidence,	 on	 the	 basis	 of	 the	 phred	 quality	 score	 (Q)	 present	 in	 the	FASTQ	file,	where	the	Q	values	is	logarhytmically	related	to	the	base	calling	error	probability	 (P).	 The	 reads	 selected	were	 then	 assembled	 into	 transcripts	when	the	reference	genome	is	not	available	or	aligned	to	reference	genome.	When	the	reference	 genome	 is	 available	 the	 first	 step	 is	 the	 reassignment	 of	 the	 DNA	fragment	 extracted	 to	 their	 original	 location	 in	 the	 genome,	 step	 called	 “reads	alignment”.	Once	aligned,	the	transcript	levels	for	each	genes	were	normalized	to	reflect	 the	 relative	 abundance	 of	 the	 transcripts	 in	 the	 starting	 library,	 also	 in	function	of	 the	transcript	 length	and	the	total	number	of	mappable	reads	 in	the	experiment,	obtaining	the	RPKM	measure	(reads	per	kilobase	of	exon	model	per	million	 mapped	 reads)	 which	 also	 allows	 comparison	 among	 different	experiment	(Mortazavi	et	al.,	2008)		
	
Figure	 intro	 9.	 RPKM	 formula	 where	 C=	 number	 of	 mappable	 reads	 into	 the	gene’s	exons,	N=total	number	of	mappable	reads	 in	the	experiment,	L=length	of	the	transcript	in	bp			Generally	 the	 final	 goal	 of	 an	 RNA-seq	 experiment	 is	 the	 identification	 of	differentially	 expressed	 genes	 among	 conditions	 such	 as	 treated	 vs	 control,	
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disease	 vs	 healthy,	 treatment	 #1	 vs	 treatment	 #2.	 The	 goal	 of	 this	 analysis	(known	 as	 differential	 expression,	 DE)	 is	 the	 identification	 of	 statistically	significant	transcriptional	variability	among	the	samples.	Since	the	appearance	of	the	 NGS	 many	 statistical	 methods	 based	 on	 Poisson	 distribution,	 negative	binomial	distribution	have	been	proposed	and	compared	and	the	debate	for	the	correct	one	is	still	open.			
ACUTE	PROMYELOCYTIC	LEUKEMIA	
Acute	 myeloid	 leukemia	 (AML)	 is	 a	 genetically	 heterogeneous	 disorder,	characterized	 by	 the	 accumulation	 of	 genetic	 alteration	 in	 hematopoietic	 stem	and/or	progenitor	cells.	The	main	characterization	of	AML	is	a	severe	block	in	the	differentiation	and	rapid	clonal	proliferation	and	expansion	of	immature	myeloid	cells	 in	 the	 bone	 marrow	 and	 peripheral	 blood.	 This	 expansion	 occurs	 at	 the	expense	of	the	normal	production	of	their	terminally	differentiated	counterparts.				
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Figure intro 10. a The general hierarchical structure of normal haematopoiesis 
comprises the long-term haematopoietic stem cells (HSCs), with extensive self-
renewal potential, that give rise to various haematopoietic progenitor cells. These 
progenitor cells maintain the proliferative ability but have lost self-renew capability. 
Progenitors produce various precursor cells and then mature haematopoietic cell types.  
b. Aberrant haematopoiesis in acute myeloid leukaemia (AML). Leukaemic stem cells 
(LCSs) reside at the top of the developmental pyramid, giving rise to AML progenitor 
cells and the more mature (but still morphologically primitive) myeloid blast cells that 
make up the bulk of the neoplasm. DC, dendritic cell; NK, natural killer. (Khwaja et 
al., 2016) 	Diagnosis	 is	 based	 on	 accumulation	 of	 myeloblasts	 in	 the	 bone	 marrow	 and	blood,	 while	 immunophenotyping	 and	 cytogenetic	 and	 molecular	characterization	 of	 myeloblasts	 are	 used	 to	 distinguish	 AML	 from	 other	leukemias	or	 to	define	AML	subtypes.	The	FAB	classification	(French-American-British)	characterized	the	AML	subtypes	based	mainly	on	cytological	features	of	
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the	expanding	population.	The	WHO	classification	superseded	the	previous	FAB	classification	and	defines	 seven	main	subtypes	of	AML	based	 largely	on	genetic	criteria	 (such	 as	 chromosomal	 translocation)	 along	 with	 morphological,	immunological,	cytochemical	and	clinics	characteristics.		Acute	promyelocitic	leukemia	(APL)	is	a	subtype	of	acute	myeloid	leukemia,	with	specific	 clinical	 and	 biological	 features,	 characterized	 by	 accumulation	 of	progenitors	 blocked	 at	 the	 promyelocitic	 state.	 The	 genetic	 hallmark	 of	 the	disease	 is	 the	 balanced	 reciprocal	 translocation	 t(15;17)(q22;q12),	 present	 in	about	95%	of	the	patient,	involving	the	promyelocytic	leukemia	(PML)	gene	and	the	 retinoic	 acid	 receptor	 alpha	 (RARa)	 gene	 (Minucci	 and	 Pelicci,	 2007).	 The	result	 of	 these	 chromosomal	 branches	 causes	 the	 creation	 of	 the	 fusion	oncoprotein	PML-RAR	(PR)		(De	The,	Chomienne	et	al.	1990),	responsible	for	the	block	of	differentiation	of	leukemic	promyelocytes.	In	vitro	studies	demonstrated	that	 PR	 confers	 self	 renewal	 abilities	 to	 murine	 CMP	 and	 GMP	 progenitors,	enhancing	 their	 colony	 forming	 capacity	 (Welch	 et	 al.,	 2011)	while	 in	mice	 the	expression	of	 the	 fusion	protein	 leads	 to	APL	development,	with	a	 intermediate	pre-leukemic	phase	without	 evident	phenotype,	 suggesting	 that	 other	mutation	are	 required	 for	 the	 onset	 of	 the	 disease	 (Di	 Croce	 et	 al.,	 2002;	 Grignani	 et	 al.,	1998).			
	
PML-RAR	oncogenic	potential	The	 fusion	 protein	 contains	 all	 the	 functional	 domains	 of	 both	 the	 parental	proteins	 and,	most	 important,	 retains	 the	 ability	 to	 bind	DNA	and	 to	 recruits	 a	wide	 spectrum	 of	 chromatin	 modifiers	 proteins	 (such	 as	 HDAC-containing	
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complexes,	DNMTs,	histone	methyltransferases,		polycomb	group	proteins)	which	allow	the	 formation	of	a	condensed	chromatin	structure,	not	permissive	 for	 the	transcription	 of	 target	 genes.	 The	 repression	 of	 the	 RAR	 target	 genes	 becomes	constitutive	 in	 the	 presence	 of	 the	 fusion	 protein	 due	 to	 its	 non-sensitivity	 to	physiological	doses	of	 retinoic	acid.	Pharmacological	doses	of	RA	are	needed	 to	release	 the	 co-repressor	 and	 recruitment	 of	 co-activators	 that	 lead	 to	transcriptional	 reactivation	 of	 the	 target	 genes	 and	 proteosomal-dependent	degradation	of	the	fusion	protein.	Two	different	studies	demonstrated	that	the	x-RAR/RXR	 heterooligomerization	 is	 required	 for	 the	 X-RAR	 fusion’s	 oncogenic	activity	(Zhu	et	al.,	2007;	Zeisig	et	al.,	2007).	PML-RAR	shows	more	relaxed	DNA	binding	 properties	 than	 wild	 type	 RAR.	 ChIP	 sequencing	 for	 PR	 and	 RXR	 in	primary	APL	cells	provides	 the	evidence	 that	PML-RAR/RXR	oligomers	 interact	on	a	 large	portion	of	genomic	 regions	 (Martens	et	al.,	2010).	Moreover	another	genome	wide	distribution	analysis	reveals	 that	PR	 is	recruited	 to	non-canonical	RAR	binding	motif,	 highlighting	 an	 increased	pattern	of	 target	 genes	 respect	 to	RAR	(Mikesh	et	al.,	2010).		
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Figure	 intro	 11.	 a.	 Structure	 of	 the	 promyelocytic	 leukemia	 (PML)	 and	 the	retinoic	 acid	 receptor-a	 (RARa)	 proteins.	 The	 PML-RARa	 fusion	 protein	comprises	 the	 RING	 (R)	 domain,	 the	 B	 boxes	 (B)	 and	 coiled-coil	 domain	 (CC),	RARa	 DNA-binding	 domain	 (C),	 hormone-binding	 domain	 (E)	 and	 other	regulatory	 domain.	 	 The	 fusion	 protein	 retains	 the	 functional	 domains	 of	 both	proteins	 allowing	 dominant-negative	 activities	 on	 both	 PML	 and	 RARa.	 b.	 The	PML-RARa	 homodimers	 bind	 and	 repress	 RARa	 target	 genes	 also	 through	recruitment	of	co-repressor.	Retinoic	acid	(RA)	at	pharmacological	doses	allows	fusion	 protein	 degradation,	 recruitment	 of	 co-activators	 and	 restores	differentiation	(De	Thé	and	Chen,	2010)	
	
APL	treatment	First	studies	 for	 the	APL	treatment	with	all-trans	retinoic	acid	(ATRA)	began	 in	the	1980s	and	demonstrated	that	ATRA	induces	terminal	differentiation	towards	granulocytes	 and	mature	 granulocyte-like	 cells,	with	 subsequently	 apoptosis	 in	vitro	e	 in	vivo	(Wang	ZY	and	Chen	Z,	2008).	Thus	ATRA	treatment	 for	APL	was	the	 first	 successful	 differentiation	 therapy	 in	 human	 cancer,	 although	 a	 high	number	of	patients	show	ATRA	resistanse	relapsed	APL	after	the	treatment.	The	treatments	with	 RA	 alone	 generally	 resulted	 in	 transient	 disease	 clearance	 but	only	 few	definitive	 cures,	while	 the	 combination	of	RA	with	anthracyclines	was	later	able	to	cure	more	than	70%	of	the	patients.	Then,	after	the	introduction	of	arsenic	 trioxide	 as	 a	 second-line	 or	 consolidation	 agent	 in	 1994,	 the	 rates	 of	patient	 that	 reached	 complete	 remission	 increased	 to	 95%	 (Sanz	 and	 Lo-Coco,	2013).	 Both	 ATRA	 and	 arsenic	 target	 the	 stability	 of	 PML-RAR	 through	 two	different	mechanisms:	ATRA	 induce	PML-RAR	degradation	via	 its	RARA	moiety,	while	arsenic	acts	on	the	PML	part	of	 the	 fusion	protein	(Zhang	et	al.,	2010).	 In	the	last	years,	thanks	to	transplantation	experiment	it	has	become	evident	that	all	the	leukemia	cells	are	not	equal	and	that	there	is	a	hierarchy	in	myeloid	leukemia	as	 in	 normal	 hematopoiesis,	 opening	 the	 way	 to	 the	 new	 concept	 of	 LICs,	leukemia	initiating	cells,	a	subpopulation	of	cells	able	to	reconstitute	the	disease	
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in	a	second	recipient	mice.	Thus,	the	eradication	of	LICs	has	been	proposed	now	as	the	new	goal	for	the	eradication	of	the	disease.	Recent	study	demonstrate	that	treatment	 with	 low	 doses	 of	 retinoic	 acid	 leads	 to	 differentiation	 of	 the	 cells,	while	treatment	with	arsenic	leads	to	loss	of	LICs	but	only	partial	differentiation.	Instead	high	doses	of	 retinoic	 acid	or	 low	doses	 combined	with	 arsenic	 lead	 to	loss	of	the	leukemia	initiating	cell,	differentiation	and	eradication	of	APL	(Ablain	and	 De	 Thé,	 2011).	 Moreover	 new	 study	 suggested	 that	 the	 transcriptional	activation	of	PR	target	genes	and	degradation	of	 the	protein	are	not	associated:	the	transcriptional	activation	seems	to	be	associated	with	differentiation	activity	while	 the	 degradation	 of	 the	 protein	 seems	 to	 be	 responsible	 for	 the	 LIC	clearance	(Nasr	et	al.,	2008;	Ablain	et	al.,	2013).	The	evaluation	of	the	combined	therapy	 RA/arsenic	 is	 underway	 while	 alternative	 therapies	 are	 under	investigation.	Since	the	importance	in	leukemogenesis	of	epigenetic	enzyme	and	histone	modifications,	new	strategies	point	to	epigenetic	target	as	a	the	strategy	for	the	development	of	new	compound	that	alone	or	in	combination	can	be	added	to	the	standard	therapy	of	APL	(Mercurio	et	al.,	2010).			
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AIMS	
	
Taking	advantage	of	a	new	LSD1	inhibitor	showing	high	specificity	and	acting	at	relatively	 low	concentrations	(Binda	et	al.,	2010)	we’ve	been	able	to	 investigate	the	 role	 of	 LSD1	 in	APL.	We	use	 as	model	 system	NB4	 cells,	 a	 cell	 line	derived	from	 APL	 patient,	 which	 recapitulate	 numerous	 characteristics	 of	 APL	 blasts	(Lanotte	et	al,	1991).	 	The	expression	of	the	PML-RAR	fusion	protein	makes	the	cells	 insensitive	 to	 physiological	 doses	 of	 retinoic	 acid	 (RA	 low	 doses)	 while	higher	 concentration	 (RA	 high)	 causes	 the	 growth	 arrest	 and	 terminal	differentiation.		The	 thesis	 started	 from	 the	 initial	 observation	 that	 treatment	 with	 LSD1	inhibition	 sensitizes	 NB4	 cells	 to	 physiological	 doses	 of	 retinoic	 acid	 which	impairs	 cell	 growth	 and	 triggers	 cell	 to	 differentiation	 with	 an	 effect	 event	stronger	compared	to	RA	high	alone	(Binda	et	al.,	2010).			To	investigate	the	role	of	LSD1	and	its	molecular	mechanism	in	this	phenomenon	of	sensitization	we	performed	genome	wide	profiling	of	 the	protein	and	of	both	transcriptional	and	epigenetic	changes	accompanying	the	LSD1	inhibition	and	the	other	 treatment	 (DMSO	as	 control,	 retinoic	 acid	 at	 low	and	high	 concentration,	and	 combination	 of	 LSD1	 inhibition	 and	 RA	 low).	Moreover	we	 investigate	 the	interaction	between	LSD1	and	the	fusion	protein	PML-RARalpha.		The	thesis	aims	to	validate	the	role	of	LSD1	in	the	differentiation	of	APL,	identify	the	transcriptional	pathways	involved,	characterized	the	interplay	between	LSD1	and	 the	 fusion	protein	 and	define	 the	molecular	mechanism	and	 the	 chromatin	changes	caused	by	LSD1	that	mediate	the	differentiation.		
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RESULTS	
	
LSD1	 INHIBITION	 SENSITIZES	 APL	 CELLS	 TO	 PHYSIOLOGICAL	 CONCENTRATIONS	 OF	
RETINOIC	ACID	
	We	previously	demonstrated	that	 inhibition	of	LSD1	sensitizes	APL-derived	cell	line	 NB4	 to	 retinoic	 acid	 treatment	 and	 induces	 cell	 growth	 arrest	 and	differentiation	when	combined	with	physiological	concentration	of	retinoic	acid	(Binda	 et	 al.	 2010).	 We	 found	 that,	 while	 NB4	 cells	 are	 not	 sensitive	 to	 LSD1	inhibition	 or	 to	 physiological	 doses	 of	 retinoic	 acid,	 the	 combination	 of	 LSD1	inhibition	 and	 retinoic	 acid	 at	 low	 concentration	 (from	 now	 on:	 cotreatment)	significantly	 reduces	 the	 cell	 proliferation	 in	 liquid	 culture	 and	 colony	 forming	ability	in	semi-solid	cloture,	with	an	effect	even	stronger	than	the	retinoic	acid	at	high	concentration	(Figure	1	a-b).		
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Figure	1:	 a.	Growth	curve	of	NB4	cells	treated	as	indicated	with	LSD1	inhibitor	DDP_10147	and/or	retinoic	acid	10nM	and	1uM.	Slopes	were	found	significantly	different:	the	comparison	between	LSD1+RAlow	and	RAhigh	was	significant	at	p-value	of	0.0028	b.	Colony	forming	ability,	scored	after	7	days,	of	1000	NB4	cells	plated	 in	methylcellulose	medium	 and	 treated	with	 LSD1	 inhibitor	 DDP_10147	and/or	 retinoic	 acid	 10nM	 and	 1uM.	 Mean	 and	 standard	 deviation	 of	 three	independent	 experiments	 are	 shown	c.	Analysis	 of	 CD11b	mRNA	 levels	 in	NB4	cells	 treated	 as	 described	 for	 24	 hours.	 Fold	 changes	were	 normalized	 against	DMSO	 and	 GAPDH	 (used	 as	 housekeeping).	 Graph	 represent	 the	 mean	 and	standard	deviation	of	three	independent	experiments.				To	 assess	 whether	 the	 observed	 phenotype	 was	 due	 to	 induction	 of	 myeloid	differentiation,	 we	 checked	 the	 CD11b	 marker	 level	 by	 qPCR	 (Figure	 1c).	 The	histogram	 in	 figure	 1b	 clearly	 shows	 an	 increase	 in	 the	 CD11b	 level	 after	 24	hours	of	treatment	with	LSD1	inhibition	plus	retinoic	acid	at	 low	concentration.	These	 data	 together	 with	 the	 strong	 differentiation-associated	 morphological	changes	 observed,	 demonstrate	 a	 clear	 synergistic	 effect	 between	 the	 LSD1	inhibition	and	the	physiological	concentration	of	retinoic	acid	in	the	induction	of	differentiation	 and	 growth	 arrest	 of	 NB4	 cells,	 even	 stronger	 than	 the	 effect	induced	by	pharmacological	doses	of	retinoic	acid.		
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A	TRANSIENT	WAVE	OF	LSD1	INHIBITION	IS	SUFFICIENT	TO	INDUCE	APL	CELL	SENSITIVITY	
TO	PHYSIOLOGICAL	RETINOIC	ACID	CONCENTRATION	
	We	 perform	 washout	 experiment	 to	 define	 the	 temporal	 window	 after	 LSD1	inhibition	 sufficient	 to	 commit	 NB4	 cells	 to	 differentiation	 in	 the	 presence	 of	physiological	 concentration	 of	 retinoic	 acid.	 NB4	 cells	 were	 treated	 with	 LSD1	inhibition	and	retinoic	acid	low,	then	the	inhibitor	was	removed	at	different	time	point	 while	 retinoic	 acid	 was	 kept	 continuously	 in	 the	 medium	 for	 96h.	 Short	periods	 of	 LSD1	 inhibition	 (6h	 and	 12h)	 were	 not	 sufficient	 to	 trigger	differentiation	of	NB4	cells	while	treatment	with	LSD1	inhibitor	 for	24	hours	 in	presence	of	retinoic	acid	at	low	concentration	leads	to	a	response	comparable	to	96	hours	of	 continuous	 co-treatment	 (Figure	2b).	 For	 these	 reason	we	 selected	24h	time	point	as	the	treatment	condition	for	all	the	following	experiments.	
	
Figure	2:	 a.	Schematic	representation	of	wash	out	experiments.	NB4	cells	were	treated	with	RA	low	for	96h	and	DDP-10147	at	2	μM		for	6h,	12h,	24h	and	96h.	The	inhibitor	has	been	washed	out	after	the	indicated	time-points	and	was	used	at	 the	 concentration	 of	 2	 μM,	 in	which	has	 been	 shown	 to	 reach	 the	maximum	target	modulation	(Binda	et	al,	2010).	b.	NB4	Cells	were	counted	at	96h.	24h	of	LSD1	 inhibition	 is	 sufficient	 to	 induce	 similar	 growth	 arrest	 to	 the	 longer	
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treatment	 where	 the	 inhibitor	 is	 kept	 in	 the	 medium	 for	 96h.	 Error	 bars	represent	SD	of	four	independent	experiments.		
COTREATMENT	 WITH	 LSD1	 INHIBITION	 AND	 PHYSIOLOGICAL	 CONCENTRATION	 OF	 RA	
ACTIVATES	THE	TRANSCRIPTIONAL	DIFFERENTIATION	PROGRAM	OF	NB4	CELLS	
	Given	the	results	of	the	washout	experiment,	we	determine	the	gene	expression	profile	of	NB4	cells	after	24	hours	of	 treatment	with	DDP-10147	and/or	RAlow	by	RNA-Seq.		Since	LSD1	has	been	generally	associated	with	transcriptional	repression,	we	first	assessed	 if	 LSD1	 target	 genes	 were	 relatively	 less	 expressed	 compared	 to	 the	LSD1	unbounded	ones.	Unexpectedly	we	observe	 the	same	 transcriptional	 level	of	 the	 LSD1-target	 genes	 (identify	 by	 LSD1	 ChIP-seq,	 see	 next	 paragraph)	compared	to	the	non-target	ones	(Figure	3)	both	considering	up-regulated	genes	and	down-regulated	genes.			
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Figure	 3:	 Boxplots	 indicate	 expression	 levels	 in	 Log2	 fold-change	 of	 FPKM	respect	 DMSO	 of	 genes	 up-regulated	 (a)	 or	 down-regulated	 (b)	 in	 at	 least	 one	treatment.	Genes	are	divided	in	LSD1	positive	(green)	or	negative	(blue)	based	on	peaks	annotation	(peak	within	22kb	upstream	or	in	the	gene	body)		Since	there	were	no	differences	in	the	expression	of	LSD1	target	genes	and	non-target	genes,	the	subsequent	analysis	has	been	made	without	further	subdivision.		Global	 analysis	 of	 the	 differentially	 expressed	 genes	 (Figure	 4a)	 revealed	 that	overall	the	majority	of	the	regulated	genes	are	up-regulated	respect	to	DMSO	and	are	 differentially	 modulated	 among	 the	 different	 treatment	 (Figure	 4b),	 while	down-regulated	 genes	 show	 a	 constant	 trend	 both	 in	 the	 number	 and	 in	 the	intensity	 of	modulation	 after	 the	 different	 treatments,	 except	 for	 the	 treatment	with	 inhibitor	 that	 shows	 only	 one	 down-regulated	 gene.	 For	 this	 reason	 we	decide	to	focus	our	analysis	on	the	up-regulated	genes.	In	order	to	better	understand	the	global	modulation	in	the	genes	expression	we	perform	 a	 heatmap	 showing	 all	 the	 genes	 regulated	 in	 at	 least	 one	 of	 the	 four	treatments	(Figure	4c,	n=	1235).	The	heatmap	highlight	the	association	of	LSD1	with	almost	all	the	regulated	genes	(green	flag	on	top	of	the	heatmap)	and	a	clear	clusterization	 based	 on	 transcription	 level	 among	 the	 treatments:	 while	 LSD1	inhibition	 has	 a	 modest	 impact	 on	 the	 global	 gene	 regulation	 and	 is	 almost	comparable	to	DMSO,	treatments	with	retinoic	acid	at	low	and	high	concentration	and	 cotreatment	 with	 LSD1	 and	 RAlow	 show	 a	 similar	 pattern	 of	 expression.		However	cotreatment	shows	a	clear	distinct	pattern	of	expression	compared	 to	all	 the	 other	 treatments	 and	 includes	 almost	 all	 the	 regulated	 genes.	 It	 is	noteworthy	 that	 the	 two	 treatments	 (cotreatment	 and	 RA	 high)	 leading	 to	 cell	differentiation,	share	many	of	the	upregulated	genes.	However	it	is	also	clear	that	
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the	 cotreatment	 leads	 to	 an	 upregulation	 of	 a	 subset	 of	 genes,	 which	 are	 not	activated	after	treatment	with	retinoic	acid	at	high	concentrations.	
	
	
Figure	 4:	 a.	 RNA	 sequencing	 was	 performed	 in	 NB4	 cells	 treated	 with	 DDP-10147,	 Ralow,	 Rahigh	 and	 DDP-10147+Ralow	 for	 24h.	 Barplot	 represents	number	 of	 genes	 regulated	 (up	 or	 down	 regulated	 respect	 to	 control	 DMSO,	
D
D
P
−1
01
47
RA
low
D
D
P
−1
01
47
/
RA
low
RA
hig
h
D
D
P
−1
01
47
RA
low
D
D
P
−1
01
47
/
RA
low
RA
hig
h
−4
−2
0
2
4
6
8
up-regulated
down-regulated
Lo
g2
 F
C
 v
s 
D
M
S
O
N
um
be
r 
of
 g
en
es
200
400
600
800
D
D
P
-1
01
47
R
A
 lo
w
D
D
P
-1
01
47
/
RA
low R
A
 h
ig
h
up-regulated
down-regulated
	 43	
RPKM>0.5,	 absolute	 (FC)>1.5,	 FDR<0.5)	 upon	 the	 indicated	 treatments.	 b.	Boxplot	shows	degree	of	induction	by	the	indicated	treatment	vs	control	(DMSO).	
c.	 Heatmap	 shows	 clusterization	 of	 gene	 regulated	 in	 at	 least	 one	 of	 the	 four	treatments	 against	 the	DMSO.	The	expression	 levels	 range	 from	 light	blue	 (less	expressed)	 to	 dark	 blue	 (more	 expressed)	 while	 the	 green	 flag	 represent	 the	LSD1	binding.		
	Contrary	to	what	happens	with	LSD1	inhibition	alone,	that	has	very	modest	effect	on	transcription	both	considering	number	of	up-regulated	genes	and	magnitude	of	 their	regulation,	 treatment	with	 the	 inhibitor	greatly	potentiates	 the	effect	of	physiological	 concentration	 of	 retinoic	 acid,	 increasing	 the	 number	 and	 the	magnitude	of	the	genes	regulated	by	RA	alone.	Consistently	with	biological	data	that	 indicate	 a	 more	 efficient	 effect	 of	 the	 combination	 in	 arresting	 cell	proliferation,	the	transcriptional	changes	induced	by	cotreatment	are	comparable	and	even	stronger	than	those	induced	by	RA	high.		
	
Figure	 5:	 Venn	 diagrams	 illustrate	 the	 similarity	 of	 genes	 expression	 changes	caused	by	RAhigh	and	RAlow	 (a)	 and	 cotreatment	 and	Rahigh	 (b).	 Genes	were	considered	 upregulated	 if	 RPKM>0.5,	 absolute	 (FC)>1.5	 respect	 to	 DMSO,	FDR<0.5.	c.	 Ingenuity	Pathway	Analysis	of	genes	regulated	by	both	RA	high	and	cotreatment	(486	genes,	violet)	and	cotreatment-only	(382,	lightblue)		
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To	further	explore	the	transcriptional	induction	effect	of	the	different	treatment	we	 compared	 the	 genes	 upregulated	 among	 the	 different	 treatment.	 Almost	 all	the	 genes	 upregulated	 by	 retinoic	 acid	 at	 low	 doses	 are	 also	 upregulated	 by	RAhigh	(Figure	5a),	showing	that	RAlow	starts	the	induction	of	genes	involved	in	cell	 differentiation	 but	 not	 sufficiently	 to	 activate	 the	 differentiation	 program.	Importantly,	in	the	same	manner	almost	all	the	genes	upregulated	by	RAhigh	are	upregulated	also	by	cotreatment	(Figure	5b),	and	this	overlap	includes	also	107	out	 of	 173	 of	 the	 genes	 induced	 by	 RAhigh	 but	 not	 by	 RAlow	 and	 probably	responsible	 for	 the	 differentiation.	 In	 addition	 to	 the	 overlapped	 genes	 with	RAhigh	 the	 cotreatment	 regulated	 also	 a	 specific	 subset	 of	 genes	 (n=382).	 This	observation	 suggests	 that	 the	 differentiation	 program	 induced	 by	pharmacological	doses	of	 retinoic	 acid	 is	 the	 same	one	 induced	by	 cotreatment	that	in	addition	activates	another	subset	of	genes	cotreatment-specific	that	could	explains	the	stronger	biological	effect	observed.	Gene	 ontology	 performed	 on	 overlapping	 genes	 (n=486)	 and	 combination	treatment-specific	 genes	 (n=382)	 revealed	 among	 the	 top	 scoring	 network	enriched	hematological	system	and	function,	tissue	morphology	and	immune	cell	trafficking	for	both	the	subset	of	genes	(Figure	5c).		
LSD1	GENOMIC	DISTRIBUTION		In	 order	 to	 explore	 the	 role	 of	 LSD1	 we	 decided	 to	 assess	 the	 genomic	distribution	 of	 LSD1	 and	 to	 correlate	 the	 obtained	 results	 with	 transcriptomic	profiling	 and	 with	 the	 histone	 modifications	 associated	 with	 its	 enzymatic	activity.	Thus	we	performed	ChIP-seq	 for	LSD1	 in	untreated	 (DMSO)	NB4	 cells.	
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After	 the	 peakcalling	 we	 perform	 q-PCR	 on	 several	 regions	 in	 order	 to	 set	 a	threshold	 for	 the	 identification	 of	 high	 confidence	 peaks	 (Figure	 6a).	 Using	 the	threshold	of	-log10(p)=16.9	we	validated	15.187	regions	of	LSD1	binding.	Peaks	annotation	performed	with	GIN	(Cesaroni	et	al.,	2008)	revealed	that	45%	of	the	peaks	are	proximal	to	the	TSS	(considered	as	+/-	2.5	Kb)	of	annotated	genes	and	about	 35%	 lay	 in	 intergenic	 and	 intronic	 regions	 (Figure	 6b),	 possibly	representing	 regulative	 regions	 and	 consistent	 with	 other	 finding	 in	 mESC	(Whyte	et	al,	2012).	This	proportion	in	the	genomic	annotation	is	not	affected	by	the	peaks	score	and	remain	constant	among	highly	enriched	peaks	and	the	rest	of	the	peaks,	highlighting	that	LSD1	more	enriched	peaks	are	not	preferentially	bind	to	specific	genomic	location	(Figure	6c).	Moreover	we	could	identify	two	different	types	of	LSD1	peaks,	sharp	and	multiple	or	broad,	with	majority	of	broad	peaks	located	 on	 TSS	 proximity	 (Figure	 6d).	 Nevertheless	 both	 the	 broadness	 of	 the	peaks	 and	 the	 number	 of	 sharp	 peaks	 associated	 to	 genes	 are	 not	 related	 to	change	in	genes	expression	(data	not	shown).	
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Figure	6:	a.	Validation	by	ChIP-qPCR	assay	of	LSD1	positive	regions	at	several	p-values	(obtained	with	MACS	peakcalling)	in	three	independent	experiments.	First	region	represent	an	intergenic	region	negative	for	LSD1	used	as	control,	anti-IgG	antibody	was	 used	 as	mock	 control.	 The	 red	 line	was	 set	 as	 the	 enrichment	 of	negative	control	plus	three	times	the	relative	SD.	26/30	regions	were	considered	as	 validated.	 (The	 four	 arrows	 point	 the	 4	 regions	 not	 validated).	 b.	 Genomic	distribution	of	LSD1	validated	peaks.	Regions	spanning	around	the	TSS	(+/-	2.5	kb)	 were	 considered	 as	 promoters,	 while	 intergenic	 regions	 correspond	 to	regions	more	than	22kb	distant	from	the	nearest	gene	c.	Genomic	distribution	of	LSD1	peaks	across	 the	different	p-value	 score.	d.	 Plot	 indicates	variation	of	 the	peaks	length	among	the	different	distance	from	TSS.	e.	PSCAN	motif	discovery	on	genomic	regions	bounded	by	LSD1.			
Since	LSD1	has	been	shown	to	cooperate	with	several	transcription	factors	(TFs)	in	hematopoiesis	(Saleque	et	al.,	2007)	we	performed	transcription	factor	binding	sites	 enrichment	 analysis	 on	 the	 LSD1	 bound	 regions.	 The	 analysis	 was	performed	 using	 PSCAN-ChIP	 algorithm	 (Zambelli	 et	 al.,	 2013)	 in	 order	 to	 find	over-represented	transcription	factor	binding	site.	The	algorithm	scans	the	given	LSD1	peaks	coordinates	and	looks	for	over	represented	sequence	motif,	based	on	motif	 descriptors	 of	 the	 TRANSFAC	 (Matys	 et	 al.,	 2003)	 and	 JASPAR	 database	
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(Portales-Casamar	 et	 al.,	 2010).	 Results	 of	 the	 scanning	 on	 regions	 bound	 by	LSD1	revealed	a	large	number	of	transcription	factor	involved	in	granulocytic	and	monocytic	 differentiation	 as	 PU.1,	 FLI1,	 GFI1,	 CEBPE.	 Moreover	 among	 the	significantly	 enriched	 matrices	 we	 found	 also	 REST,	 a	 known	 LSD1	 recruiter	(Mosammaparast	 and	 Shi	 2010),	 IRF8	 and	 the	 canonical	 PML-RAR	 binding	sequences	 (RAR:RXR	 DR5)	 suggesting	 an	 interaction	 between	 PML-RAR	 and	LSD1,	at	least	in	certain	genes	and	confirm	the	key	role	of	LSD1	in	hematopoietic	regulation.		
	
LSD1	INHIBITION	CAUSES	A	GLOBAL	INCREASE	IN	THE	HISTONE	H3K4	DIMETHYLATION	
	Since	 from	 RNA-seq	 analysis	we	 observed	 that	 LSD1	 inhibition	 alone	 does	 not	dramatically	 alter	 transcription	 of	 NB4	 cells	 but	 has	 a	 great	 impact	 in	combination	 with	 retinoic	 acid,	 we	 reasoned	 that	 the	 contribution	 of	 LSD1	inhibition	should	be	investigated	in	the	chromatin	alteration	occurring	after	the	treatment.	For	this	reason	we	performed	ChIP-seq	for	H3K4me1/me2/me3	and	H3K27	 acetylation	 after	 LSD1	 inhibition,	 RAlow,	 combination	 of	 the	 two	treatments	 and	 RAhigh.	 	 Peakcalling	 analysis	 respect	 to	 DMSO	 revealed	 a	significant	increase	of	the	number	of	the	H3K4me2	peaks	in	regions	bounded	by	LSD1	after	inhibition	while	the	other	histone	modification	are	only	little	affected	by	the	treatment.	Similarly,	we	observed	a	significantly	increase	of	the	number	of			H3K27ac	regions	after	RA	low	treatments.	Only	after	treatment	with	combination	of	 LSD1	 inhibition	 and	 physiological	 doses	 of	 retinoic	 acid	 we	 observed	 an	increase	 of	 both	 the	 histone	 marks	 H3K4me2	 and	 H3K27ac	 (Figure	 7).	 These	observations	and	 the	biological	 results	 that	 individuate	cotreatment	as	 the	only	
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one	 with	 cell	 differentiation,	 led	 us	 to	 hypothesize	 that	 the	 individual	contribution	 of	 the	 two	 treatments,	 increase	 of	 H3K4me2	 by	 the	 inhibitor	 and	increase	 of	 H3K27	 by	 retinoic	 acid,	 which	 individually	 has	 no	 effect	 on	transcription	nor	on	differentiation,	once	combined,	leads	to	the	activation	of	the	differentiation	 program	 in	NB4	 cells.	 Thus	 the	 presence	 of	 both	H3K4me2	 and	H3K27ac	 could	 be	 a	 prerequisite	 for	 the	 transcriptional	 activation	 and	 cells	differentiation.		
	
Figure	 7:	 ChIP-seq	 of	 indicated	 histone	modifications	were	 performed	 in	 NB4	cells	 treated	 with	 DDP-10147,	 Ralow,	 Rahigh	 and	 DDP-10147+Ralow	 for	 24h.	Barplot	represents	number	of	regions	(peaks)	increasing	in	mono-,	di-,	tri-methyl	K4	of	histone	H3	and	acethylation	of	K27	of	histone	H3	peaks	 in	LSD1	positive	regions.	
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LSD1	POISES	CHROMATIN	FOR	DIFFERENTIATION	BY	SELECTIVE	INCREASE	IN	H3K4ME2		
	To	further	explore	the	role	of	LSD1	on	the	chromatin	changes	and	to	correlate	the	obtained	 results	 with	 the	 transcriptomic	 profiling	 and	 cells	 differentiation	 we	decided	 to	 individuate	 the	 subset	 of	 genes	 cotreatment-specific,	 and	 thus	differentiation-related	genes,	 and	 then	explore	 the	 chromatin	 associated	 to	 this	particular	set	of	genes.	We	divided	the	up-regulated	genes	into	classes	based	on	the	transcriptional	 induction	after	the	different	treatments,	obtaining	10	classes	of	possible	combinations	of	the	three	treatments	(Table	1).			
	
Table	 1.	Number	of	genes	regulated	 inside	each	class.	One	row	 indicates	genes	upregulated	respect	DMSO	(RPKM>0.5,	Log2(FC	vs	DMSO)>1.5),	two	row	indicate	further	increase	respect	one	row	to	Log2(one	row)>1.5.	the	last	column	indicates	the	percentage	of	genes	in	each	class	upregulated	also	after	RAhigh	treatment.				Most	 of	 the	 classes	 are	 poorly	 represented	 while	 the	 majority	 of	 the	 gene	 is	included	in	the	classes	from	1	to	3.	We	individuated	a	subset	of	254	genes	named	class	1	as	cotreatment-specific	genes,	up-regulated	only	after	treatment	with	both	
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LSD1	inhibition	and	RAlow.	To	investigate	the	chromatin	changes	related	to	LSD1	in	 this	 class	 each	 gene	was	 associated	 to	 LSD1	peak	 (or	peaks)	 and	 then	 reads	coverage	 for	 all	 the	 histone	 marks	 were	 calculated	 inside	 the	 windows	delimitated	by	the	LSD1	peaks	(Peaks	were	considered	associated	to	gene	if	there	are	no	more	than	22kb	of	distance	between	them).			
		
Figure	8:	a.	Boxplot	shows	level	of	K4	dimethylation	(green)	and	K27	acetylation	(purple)	 of	 histone	 H3	 in	 regions	 LSD1	 positive	 and	 associated	 to	 genes	cotreatment-specific	 (class	 1).	 Statistics	 was	 performed	 with	 repeated	misures	ANOVA	comparing	log10	FC	of	RPKM	treatment	values	respect	to	DMSO	followed	by	 Tukey’s	 multiple	 comparison	 tests.	 b.	 Violin	 plot	 showing	 the	 degree	 of	induction	by	 the	 indicated	 treatment	vs	 control	 (DMSO)	 in	 cotreatment-specific	subset	 of	 genes	 (class	 1,	 n=	 256).	 Statistics	 were	 performed	 as	 Repeated	Measures	 ANOVA	 comparing	 log2	 FC	 of	 RPKM	 treatment	 values	 respect	 DMSO	values	 of	 each	 gene	 included	 in	 the	 class,	 followed	 by	 Tukey's	 Multiple	Comparison	Test.	 LSD1+RAlow	was	 significanly	 higher	 respect	DDP-10147	 and	RAlow	with	*	p	value	<0,0001.			Chromatin	 coverage	 in	 the	 LSD1	 binding	 site	 associated	 to	 class	 1	 revealed	 a	statistical	significant	increase	in	the	H3K4me2	after	LSD1	inhibition,	comparable	
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to	 the	 cotreatment	 level,	 while	 both	 the	 values	 significantly	 higher	 respect	 to	RAlow.	Conversely,	there	is	an	increase	in	the	level	of	H3K27ac	after	RAlow	that	is	comparable	to	cotreatment	values	but	not	present	after	LSD1	inhibition	(Figure	8a).	Only	in	presence	of	both	these	chromatin	modifications	after	cotreatment	we	observed	 increase	 in	 the	 level	of	 transcription,	 significantly	higher	 that	 the	 two	other	treatments,	in	which	only	one	modification	at	a	time	increases	(Figure	8b).	Differently	to	the	genes	comprised	in	the	other	two	classes,	regions	associated	to	class	1	are	the	only	ones	with	this	statistical	increase	in	H3K4me2	and	H3K27ac	mark,	suggesting	that	this	is	a	cotreatment-specific	phenomenon.	These	 data	 prompted	 us	 to	 propone	 a	 model	 in	 which	 LSD1	 inhibition	 poises	chromatin	for	differentiation	in	NB4	cells	by	physiological	doses	of	retinoic	acid.			
KO	RECAPITULATES	THE	RESULTS	OBTAINED	WITH	LSD1	INHIBITION	
	To	 assess	 whether	 the	 effect	 of	 the	 compound	 was	 due	 to	 its	 action	 on	 LSD1,	LSD1	was	depleted	by	CRISPR-Cas9	 (Figure	9a).	LSD1	depletion	does	not	affect	cell	growth	and	colony	forming	activity	(Figure	9	b,c),	while	sensitivity	of	NB4	to	physiological	 concentration	of	RA	was	 clearly	 enhanced	 (Figure	9	d,e).	We	also	performed	ChIP-seq	 of	H3K4me2	 and	H3K27ac	 and	RNA-seq	of	NB4	 cells	 after	LSD1	KO.	As	expected	we	observed	a	very	small	number	of	genes	affected	by	the	LSD1	KO,	comparable	with	the	level	obtained	after	treatment	with	LSD1	inhibitor	for	24h	(Figure	9	c).	Moreover,	we	observed	number	of	regions	with	enrichment	in	 H3K4me2	 comparable	 with	 the	 level	 obtained	 after	 24h	 of	 LSD1	 inhibition	(Figure	9d).	Taken	together	these	data	demonstrate	that	LSD1	depletion	mimics	
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the	effect	of	LSD1	inhibition,	confirming	a	direct	role	of	LSD1	in	RA	sensitization	of	APL	cells.		FFf
	
	
Figure	9:	RNA	and	ChIP	sequencing	was	performed	in	NB4	with	LSD1	depleted	by	CRISPR-Cas9	(genes	shared	in	two	different	replicates	are	shown).		
a.	Western	 blot	 showing	 extracts	 deriving	 from	 NB4	 wild	 type	 and	 knock	 out	cells.	 Tubulin	 has	 been	 used	 as	 loading	 control.	 b.	 Cell	 viability	 assay	(CellTiterGlo)	 of	 NB4	 wild	 type	 and	 knock	 out	 cells	 c.	 Colony	 forming	 ability,	scored	 after	 7	 days,	 of	 250	 NB4	 and	 NB4	 KO	 cells	 plated	 in	 methylcellulose	
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medium.	 Mean	 and	 standard	 deviation	 of	 three	 independent	 experiments	 are	shown	d.	Proliferation	of	NB4	wild	 type	and	LSD1	knock	out	 cells	 treated	with	10nM	retinoic	acid	and	DMSO	as	control	in	liquid	culture.	e.	Percentage	of	CD11b	positive	 cells	 assessed	by	FACS	after	24,48	and	72	hours	of	 treatment	 in	 liquid	culture.	 f.	Barplot	represents	number	of	genes	regulated	(up	or	down	regulated	respect	 to	control,	RPKM>0.5,	absolute	(FC)>1.5)	 in	 the	 indicated	treatments.	g.	Barplot	represents	number	of	regions	(peaks)	increasing	in	H3K4me2	or	in	LSD1	positive	regions.	
	
LSD1	 INHIBITION	 DRIVES	 DIFFERENTIATION	 THROUGH	 A	 SPECIFIC	 TRANSCRIPTIONAL	
PROGRAM,	PML-RAR	INDEPENDENT	
	Acute	promyelocytic	leukemia	is	characterized	in	95%	(Sanz	and	Lo	Coco,	2011)	of	 the	cases	by	 the	 translocation	 t(15;17)	 that	give	 rise	 to	 the	oncogenic	 fusion	protein	 PML-RAR.	 The	 expression	 of	 the	 fusion	 protein	 was	 proposed	 as	 the	initiating	event	in	APL	and	determines	a	differentiation	block	that	confers	major	self-renewal	 and	 growth	 properties	 to	 the	 leukemia	 clone	 leading	 to	 aberrant	proliferation	 of	 myeloid	 progenitors.	 PML-RAR	 acts	 as	 potent	 transcriptional	repressor	 that	 can	 multimerize	 and	 form	 large	 protein	 complexes	 recruiting	several	histone-modifiers,	such	as	HDAC1	(Minucci	and	Pelicci,	2007),	which	all	cooperate	to	enforce	the	transcriptional	and	epigenetic	repression.	In	presence	of	pharmacological	 doses	 of	 retinoic	 acid	 a	 conformational	 change	 occurs	 with	subsequent	 degradation	 of	 the	 fusion	 protein,	 release	 of	 corepressor	 and	recruitment	of	coactivators	that	allow	active	transcription	of	the	genes	previously	repressed	by	PML-RAR	and	rapid	cell	differentiation	in	vitro	and	in	vivo.	(Chen	et	al.,	 1991,	 Chomienne	 et	 al,	 1990).	 Contrary	 to	 what	 happens	 with	pharmacological	 doses	 of	 RA	 (RA	 high)	 that	 triggers	 PML-RAR	 to	 degradation,	physiological	doses	of	RA	 (RA	 low)	do	not	 (Nasr	and	Guillemin,	2008).	For	 this	reason,	 we	wanted	 to	 understand	 the	 effect	 of	 the	 different	 treatments	 on	 the	
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degradation	of	 the	protein	and,	 in	particular,	 if	 the	 cotreatment	determines	 the	degradation	of	the	fusion	protein	as	occurs	after	treatment	with	retinoic	acid	at	high	 concentrations,	 since	 they	 both	 the	 treatments	 drives	 APL	 cells	differentiation.	 By	 western	 blot	 (Figure	 10a)	 we	 observe	 that	 the	 PML-RAR	protein	 remained	 stable	 after	 LSD1	 inhibition	 and	 RA	 low,	 presenting	 similar	levels	 to	 DMSO	 treated	 cells,	 while	 treatment	 with	 high	 doses	 of	 retinoic	 acid	leads	 to	 a	 complete	 degradation	 of	 the	 protein	 as	 expected	 and	 already	demonstrated.	 Interestingly,	 the	protein	 level	of	PML-RAR	is	not	affected	by	the	cotreatment,	 suggesting	 that	 the	 LSD1	 inhibition	 is	 able	 to	 drive	 NB4	 cells	 to	differentiation	and	growth	arrest	in	presence	of	the	fusion	protein.		Moreover,	since	PML-RAR	exploits	 its	oncogenic	potential	ability	as	an	aberrant	transcription	 factor	 (Saeed	 et	 al.,	 2011),	we	performed	PML	ChIP-qPCR	on	 two	PML-RAR	 targets	 established	 by	 ChIP-seq,	 PRAM1	 and	 PI3KD	 (Martens	 et	 al.,		2010),	 in	 order	 to	 control	whether	 the	 protein	 still	 bind	 its	 target	 genes	 upon	cotreatement.		We	 observed	 that	 LSD1	 inhibition,	 RA	 low	 and	 cotreatment	 did	 not	 alter	 PML-RAR	recruitment,	while	RA	high	displaced	PML-RAR	from	chromatin	(Figure	10	b).	 These	 results	 clearly	 demonstrated	 that	 LSD1	 inhibition	 triggers	differentiation	and	growth	arrest	of	APL	cells	without	affecting	PML-RAR	stability	and	recruitment	on	chromatin.	To	 further	 confirm	 the	PML-RAR	 independency	of	 cell	 differentiation	driven	by	LSD1	 inhibition,	 we	 compared	 genes	 of	 class	 1,	 with	 transcriptional	 induction	only	after	cotreatment	(class	1),	and	genes	activated	by	pharmacological	doses	of	RA	(RA	high);	we	observed	a	very	 little	overlap	(17%)	between	 the	 two	sets	of	genes	(Figure	10c),	much	lower	respect	the	other	two	other	major	classes	(class	2	
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and	class	3),	suggesting	that	the	activation	of	class	1	genes	is	probably	governed	by	 different	 mechanisms,	 PML-RAR	 independent.	 In	 agreement	 with	 this	observation,	 it	 is	 interesting	 to	note	 that	class	1	genes	show	a	significant	 lower	PML-RAR	 occupancy	 (PML-RAR	 binding	 site	 derived	 from	 previously	 NB4	 by	ChIP-Seq,	 Martens	 et	 al.,	 2010)	 compared	 to	 genes	 activated	 by	 high	concentrations	of	RA	(Figure	10	d,e).				
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Figure	 10:	 a.	 Western	 blot	 showing	 PML-RAR	 level	 in	 NB4	 cells	 treated	 as	indicated	for	24h.		Tubulin	served	as	loading	control.	b.	Histogram	represents	the	ChIP-qPCR	for	PML	in	NB4	cells.	Enrichment	signal	was	normalized	versus	input.	Two	 negative	 regions	were	 used	 as	 controls	 to	 distinguish	 aspecific	 signal	 and	correspond	to	intergenic	(NEG	A)	or	intronic	(NEG	B)	PR-negative	region.	c.	Venn	diagram	represent	 the	overlap	of	genes	contained	 in	 the	different	3	classes	and	genes	 upregulated	 after	 RAhigh	 treatment.	 d.	 Barplot	 showing	 percentage	 of	PML-RAR	occupancy	 in	 the	different	3	 classes.	e.	 Stacked	barplot	 represent	 the	percentage	of	genes	PML-RAR	target	in	class	1,	cotreatment-specific	and	in	genes	upregulated	 after	 RAhigh	 treatment,	 the	 two	 percentages	 are	 significantly	different	(Fischer	exact	text	p<0.0001).			
	
THE	PRIMING	MODEL	OF	COTREATMENT-SPECIFIC	GENES	
	All	the	results	obtained	by	the	analysis	and	the	comparison	of	transcriptional	and	chromatin	 profiles	 among	 the	 different	 treatments	 allowed	 us	 hypothesize	 a	mechanistic	model	of	action	cotreatment.		In	 regions	 associated	 to	 genes	 belonging	 to	 class	 1,	 and	 then	 upregulated	 only	after	cotreatment,	the	two	treatments	alone	lead	to	the	increase	of	two	different	histone	 modifications	 H3K4me2	 and	 H3K27ac;	 the	 same	 two	 treatments	combined	 in	 a	 single	 combination	 drive	 to	 activation	 of	 transcription	 and	 cell	differentiation.	 The	 effects	 of	 the	 two	 treatments	 alone,	 LSD1	 inhibitor	 and	retinoic	 acid	 at	physiological	 concentrations,	 although	 leading	 to	 an	 increase	 in	histone	 markers	 are	 not	 sufficient	 to	 activate	 the	 genes	 responsible	 for	 cell	differentiation.	 The	 synergistic	 action	 of	 the	 two	 treatments	 leads	 to	 a	transcriptional	activation	and	cell	differentiation.	 In	addition	to	 this	model,	 that	takes	 into	 account	 the	 histone	 markers	 and	 the	 presence	 of	 LSD1,	 further	consideration	must	be	made	regarding	 the	presence	of	 the	 fusion	protein	PML-RAR.	As	already	demonstrated,	 treatment	with	 low	doses	of	 retinoic	acid	 is	not	
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sufficient	 for	 the	 degradation	 of	 the	 fusion	 protein,	 which	 is	 degraded	 instead	with	 pharmacological	 doses	 of	 retinoic	 acid,	 leading	 to	 the	 removal	 of	transcriptional	 blocking	 and	 activation	 of	 genetic	 pathways	 responsible	 for	 cell	differentiation.		Treatment	 with	 physiological	 doses	 of	 retinoic	 acid	 and	 the	 inhibitor	 of	 LSD1	determines	cell	differentiation	while	maintaining	the	fusion	protein,	which	is	not	degraded	 but	 also	 retains	 the	 binding	 with	 DNA;	 the	 contrary	 happens	 with	pharmacological	 doses	 of	 retinoic	 acid,	 that	 determines	 the	 detachment	 and	degradation	of	 the	protein.	 Cell	 differentiation	 as	 a	 result	 of	 the	 cotreatment	 is	caused	 by	 the	 activation	 of	 a	 different	 pathway	 genes	 compared	 to	 those	activated	by	retinoic	high,	and	this	probably	derives	from	the	need	to	bypass	the	transcriptional	block	caused	by	the	fusion	protein.	This	is	also	consistent	with	the	low	number	of	PML-RAR	target	genes	among	the	genes	activated	by	cotreatment.	
	 59	
	
Figure	11:	Model	summarizing	chromatin	dynamics	 in	class	1	genes	associated	regions	 upon	 the	 indicated	 treatments.	 At	 specific	 regions,	 bounded	 by	 LSD1,	treatment	with	LSD1	inhibitor	leads	to	H3K4me2	increase	while	treatment	with	low	doses	of	retinoic	acid	determined	increase	in	H3K27ac.	In	both	the	treatment	these	increase	are	not	sufficient	to	activate	the	associated	genes	and	cells	remain	undifferentiated.	Combination	of	 the	two	treatments	caused	an	 increase	 in	both	H3K4me2	and	H3K27ac	that	drive	the	activation	of	the	associated	genes	and	cell	differentiation.			
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LSD1	BINDING	IN	PRIMING	MODEL-SELECTED	REGIONS	ARE	CONSERVED	AFTER	TREATMENTS		
	The	priming	model	proposed	considers	as	positive	LSD1	genes	those	genes	that	were	 identified	 as	 protein	 binding	 site	 according	 to	 the	 ChIP-seq	 made	 on	untreated	NB4	cells	(DMSO).	The	next	question	was	whether	this	model	could	be	considered	valid	even	taking	into	account	a	possible	repositioning	of	the	protein	as	a	result	of	the	treatments.	Recent	studies	demonstrate	that	inhibition	of	LSD1	in	Kasumi-1	and	SKNO-1	cells	evict	LSD1	from	chromatin	(McGrath	et	al.,	2016).	For	this	reason	we	performed	LSD1	ChIP-seq	in	NB4	cells	after	24h	of	treatment	with	 inhibitor,	 cotreatment	and	 retinoic	 acid	at	high	 concentration.	 Similarly	 to	the	previous	LSD1	ChIP-seq	we	validate	the	peaks	obtained	with	the	peakscalling	for	 each	 treatments	 by	q-PCR	 and	 set	 the	 threshold	 to	 234,	 357,239,196	MACS	score	 respectively	 for	 DMSO,	 LSD1	 inhibitor,	 cotreatment	 and	 RAhigh.	 The	analysis	 on	 the	 peaks,	 called	 on	 the	 NB4	 input	 and	 filtered	 according	 to	 the	thresholds	 obtained	 by	 q-PCR,	 revealed	 that	 almost	 all	 the	 binding	 regions	present	in	the	DMSO	are	maintained	after	the	three	treatment	analyzed.		This	result	allowed	us	 to	confirm	that	 the	genes	and	 their	respective	regions	of	the	proposed	priming	model	were	retained	as	protein	binding	sites	even	after	the	treatments.	Thus	the	model	was	valid	also	considering	the	possible	repositioning	of	protein.	
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Figure	12:	 a.	Heatmap	shows	expression	level	of	genes	regulated	in	at	 least	one	of	the	four	 treatments	 against	 the	 DMSO	 (same	 gene	 as	 figure	 4a,	 n=1235)	 The	 expression	levels	range	from	light	blue	(less	expressed)	to	dark	blue	(more	expressed).	The	colored	flags	on	the	left	represent	the	LSD1	binding	in	the	indicated	treatment.	b.	UCSC	genome	tracks	 of	 two	 class	 1	 genes	 show	 the	maintenance	 of	 LSD1	 peaks	 among	 the	 different	treatments.				Moreover,	 to	 explore	 the	 correlation	 between	 LSD1	 and	 global	 modulation	 of	gene	expression	we	extended	the	previous	analysis	by	adding	to	the	heatmap	of	modulated	 genes	 in	 figure	 4a	 also	 the	 binding	 sites	 of	 the	 protein	 after	 the	different	 treatments	 (Figure	12a).	As	 expected	 there	 is	 no	 clustering	of	 protein	binding	compared	to	the	various	subsets	of	genes	expressed,	the	binding	does	not	appear	 to	 change	 significantly	 among	 treatments	 and	 affects	 almost	 all	 genes	
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considered	 (genes	 significantly	 expressed	 in	 at	 least	 one	 of	 the	 treatments	compared	to	DMSO,	n=1235).			
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DISCUSSION	
	
LSD1	INHIBITION	SENSITIZE	NB4	CELLS	TO	RA-INDUCED	DIFFERENTIATION	
	Our	 lab	 takes	 part	 in	 the	 development	 of	 a	 new	 compound	working	 as	 a	 LSD1	specific	inhibitor	(Binda	et	al.,	2010).	Taking	advantage	of	the	high	specificity	of	the	inhibitor	we	aimed	to	characterize	the	role	of	LSD1	in	APL	cells.	We	found,	by	morphological	characterization	and	analysis	of	differentiation-associated	marker,	that	both	LSD1	KO	and	pharmacological	 inhibition	of	 the	protein	 sensitizes	 the	NB4	 cells,	 a	 PML-RAR	 expressing	 APL	 cell	 line,	 to	 retinoic	 acid-induced	differentiation.	 	Results	 in	cell	proliferation	and	colony	 forming	ability	 revealed	an	 even	 stronger	 effect	 of	 the	 combination	 of	 LSD1	 inhibitor	 and	 RA	 acid	 at	concentration	100-fold	lower	respect	to	pharmacological	doses	of	RA,	capable	of	induce	differentiation.	We	demonstrate	that	a	pulse	of	inhibition	was	sufficient	to	prime	APL	cells	to	differentiate,	suggesting	that	LSD1	dependent	activities	play	a	role	in	the	initial	phases	of	RA	induced	differentiation.			
LSD1	GENOMIC	DISTRIBUTION	
	To	 investigate	 the	 function	of	LSD1	 in	NB4	cells,	we	 first	 identified	 the	binding	sites	 of	 the	 protein	 by	 using	 chromatin	 immunoprecipitation	 coupled	 with	massively	parallel	DNA	sequencing	(ChIP-seq).	We	found	that	LSD1	occupancy	in	APL	cells	is	mainly	promoter-associated	and	reads	density	are	higher	around	the	TSS	of	the	annotated	genes.	Nevertheless	we	also	found	a	significant	proportion	of	 LSD1	 peaks	 in	 promoter	 distal	 regions,	 in	 accordance	 with	 previous	 results	
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obtained	 in	 mESCs	 and	 immature	 murine	 granulocytic	 cell	 line	 (Whyte	 et	 al.,	2012,	 Kereniy	 et	 al.,	 2013).	 Motif	 discovery	 analysis	 revealed	 that	 promoters	bounded	by	LSD1	were	 enriched	 for	 binding	matrix	 of	 SPI1,	 EGR1	 and	E2F1-3,	transcription	 factors	 involved	 in	 the	 granulocytic/monocytic	 differentiation.	Moreover	we	also	found	REST,	a	known	LSD1	recruiter	(Mosammaparast	and	Shi	2010)	and	the	canonical	PML-RAR	binding	sequences	(RAR:RXR	DR5),	suggesting	that	 LSD1	 can	 interact	 also	with	 the	 oncogenic	 fusion	 protein	 characteristic	 of	APL,	at	least	in	the	promoters	of	certain	genes.			
CO-TREATMENT	 ACTIVATES	 THE	 TRANSCRIPTIONAL	 DIFFERENTIATION	 PROGRAM	 OF	 NB4	
CELLS	AND	DRIVE	CELL	TO	DIFFERENTIATION	
	Despite	 its	well-supported	 activity	 as	 transcriptional	 repressor,	 LSD1	binds	 are	all	 across	 the	 genome	 also	 at	 actively	 transcribed	 promoters	 and	 enhancer	(Whyte	 et	 al,	 2012).	We	 found	 indeed	 a	 large	 overlap	 between	 LSD1	 and	 PolII	occupancy,	suggesting	that	LSD1	may	cooperating	to	keep	transcription	of	target	genes	under	a	certain	 threshold	rather	 than	repressing	 it	 completely	or	 that	 its	activity	is	dynamically	counterbalanced	by	co-located	transcription	activator.	Our	RNA-seq	on	NB4	cells	treated	for	24	with	inhibitor,	retinoic	acid	or	combination	of	 the	 two	 revealed	 that	 the	 binding	 of	 the	 protein	 doesn’t	 affect	 the	 level	 of	transcription	 in	 none	 treatment	 both	 in	 up-regulated	 and	 in	 down-regulated	genes.	 We	 also	 observed	 that	 inhibition	 of	 LSD1	 by	 itself	 does	 not	 have	 a	 big	impact	 on	 the	 transcription	 but	 in	 accordance	 with	 its	 repressor	 role	 the	 few	genes	modulated	 respect	 to	 the	DMSO	 are	 up-regulated	while	 only	 one	 gene	 is	down-regulated.	 Retinoic	 acid	 at	 physiological	 concentration	 has	 only	 a	 mild	
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effect	while	we	observe	a	significant	increase	in	transcription	after	co-treatment	and	 retinoic	 acid	 at	 pharmacological	 concentrations,	 consistent	 with	 the	phenomenon	of	cell	differentiation	only	visible	as	result	of	these	two	treatments.		Interestingly	 the	 cell	differentiation	observed	after	 co-treatment	 is	 activated	by	two	different	pathways	of	genes,	one	subset	of	genes	shared	with	retinoic	acid	at	high	 concentration	 and	 the	 other	 subset	 induced	 only	 after	 co-treatment	 but	always	 related,	 as	 for	 the	 first	 subset,	 with	 hematological	 system	 development	and	function,	tissue	morphology	and	immune	cell	trafficking.		These	results	suggest	 that	 the	activity	of	LSD1	per	se	 is	not	directly	 involved	 in	transcription	 but	 has	 a	 poising	 function	 that	 contributes	 to	 the	 activation	 by	retinoic	acid	low	of	an	alternative	pathway	of	genes	specific	for	the	co-treatment	and	different	respect	retinoic	acid	at	higher	concentration.		
	
	
LSD1	INHIBITOR-DEPENDENT	EPIGENETIC	MODULATION	PRIMED	NB4	DIFFERENTIATION	
	The	 poising	 hypothesis	 suggested	 by	 transcription	 data	 is	 corroborated	 by	 the	analysis	 of	 chromatin	 alteration	 occurring	 after	 the	 different	 treatments.	 ChIP-seq	 analysis	 revealed	 a	 global	 significant	 increase	 in	H3K4me2	 after	 treatment	with	LSD1	inhibitor	alone	or	in	combination,	co-localized	with	LSD1	peaks	within	promoters	and	TSS	distal	regions.		Interesting	we	 can	 not	 observe	 this	 increase	 in	NB4	 cells	 treated	with	 retinoic	acid	at	low	concentration,	where	we	can	instead	observe	increase	in	the	H3K27ac	level,	comparable	to	the	one	observed	in	co-treatment.	It	is	important	to	note	that	this	 increase	of	H3K27ac,	generally	associated	 to	an	active	 transcription,	 in	 this	
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case	 is	 not	 correlated	 with	 the	 expression	 levels	 of	 the	 genes,	 which	 remain	comparable	to	the	control.		Since	only	the	combination	of	the	two	treatments	induces	cell	differentiation,	we	reasoned	that	the	presence	of	both	H3K4me2	and	H3K27ac	is	a	prerequisite	for	the	activation	of	the	differentiation	program	in	NB4	cells.	Moreover	this	effect	is	observed	 only	 in	 regions	 bounded	 by	 LSD1	 and	 associated	 with	 a	 subset	 of	cotreatment-specific	 genes	 and	 not	with	 RAhigh	 induced	 genes,	 indicating	 that	the	 H3K4me2	 increase	 after	 LSD1	 inhibitor	 poises	 the	 chromatin	 for	 the	activation	 by	 retinoic	 acid	 of	 an	 alternative	 pathway	 of	 genes	 responsible	 for	differentiation.				
CHARACTERIZATION	OF	LSD1	-	PML-RAR	INTERPLAY	
	APL	patients	present	in	the	95%	of	the	cases	the	expression	of	the	fusion	protein	PML-RAR	(PR)	due	to	the	translocation	t(15;17).	The	oncogenic	potential	of	 the	fusion	protein	 is	expressed	by	 the	 influence	on	both	PML	pathway	and	retinoic	acid	receptor	functions.	Treatment	with	retinoic	acid	reactivates	the	downstream	RARa	pathway-inducing	differentiation	of	APL	blasts	through	degradation	of	the	fusion	 protein,	 a	 step	 that	 has	 been	 proposed	 as	 crucial	 for	 differentiation	 and	eradication	of	APL.	At	molecular	level	only	high	(pharmacological)	concentration	of	retinoic	acid	triggers	PML-RAR	to	proteosomal	degradation	while	physiological	doses	does	not	 (Nasr	et	 al.,	 2008).	For	 this	 reason,	we	wanted	 to	understand	 if	LSD1	 inhibition	 combined	 with	 low	 doses	 of	 retinoic	 drives	 APL	 cells	differentiation	 through	 the	 degradation	 of	 PML-RAR,	 as	 RA	 high	 does.	Interestingly,	PML-RAR	protein	remained	stable	after	LSD1	inhibition,	presenting	
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similar	 levels	 to	DMSO	treated	cells,	while	 it	was	only	very	 little	affected	by	RA	low,	and	complete	degradated	by	RA	high.	Moreover	since	PML-RAR	exploits	its	oncogenic	potential	ability	as	aberrant	transcription	factor	(Saed	et	al.,	2011)	we	investigated	PML-RAR	binding	of	its	target	genes	after	the	different	treatments.		PML	ChIP-qPCR	on	PRAM1	and	PI3KD,	two	PML-RAR	targets	established	by	ChIP-Seq	(Martens	et	al.,	2010),	revealed	that	LSD1	inhibition	and	RA	low	did	not	alter	PML-RAR	 recruitment,	 while	 RA	 high	 displaced	 PML-RAR	 from	 chromatin.		Further	 confirmation	 of	 the	 independency	 of	 cell	 differentiation	 driven	 by	 the	cotreatment	 from	 the	PML-RAR	 fusion	protein	 is	 the	 little	 overlap	 of	 PML-RAR	target	genes	and	cotreatment-specific	genes	observed.	The	almost	 total	absence	of	genes	target	of	 the	 fusion	protein	and	the	 little	overlap	between	cotreatment	genes	and	genes	induced	by	RA	high,	suggest	that	the	action	of	LSD1	leads	to	an	activation	governed	by	different	mechanism	respect	 to	RA	high.	Contrary	 to	RA	high	 the	 cotreatment	 doesn’t	 altered	 the	 levels	 and	 the	 binding	 of	 the	 protein,	thus	 LSD1	 inhibition	 acts	 on	 non-target	 PML-RAR	 genes	 and	 allows	 the	 gene	activation	through	an	alternate	mechanism	which	bypasses	the	block	determined	by	the	fusion	protein.		Collectively,	our	experiments	characterized	the	role	of	LSD1	in	APL,	suggesting	a	mechanistic	interpretation	of	its	action.	LSD1	is	bound	across	almost	all	the	genes	regulated	 in	 this	 system	 upon	 differentiating	 condition	 but	 its	 binding	 doesn’t	influence	directly	the	transcription.	Its	actions	seem	to	be	selective	mediated	by	its	 H3K4me2	 demethylase	 activity	 in	 specific	 regions	 related	 to	 genes	overexpressed	 only	 after	 cotreatment.	 LSD1	 acts	 on	 these	 non-PML-RAR	 target	
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genes	overcoming	the	block	of	transcription	due	to	the	fusion	protein	and	poises	chromatin	for	a	later	phases	induction	of	differentiation	by	RA	low.																																																
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APPENDIX	
	
	 We	 extended	 in	 the	 last	 few	months	 the	 analysis	 of	 the	 chromatin	markers	also	 to	 treatment	with	 retinoic	 acid	 at	 high	 concentration	 (RA	 high),	which	shows	similar	phenotype	to	co-treatment.		The	same	analysis	performed	on	the	class	1	region	was	also	performed	on	the	ChIP-seq	of	NB4	cells	after	RA	high.	Although	 the	expression	of	 those	genes	does	not	 increase	after	RA	high	 treatment,	 the	 level	of	H3K4	di-methylation	increase	 and	 is	 comparable	 to	 the	 inhibitor	 and	 the	 co-treatment	 levels,	suggesting	 that	 this	 change	 in	 H3K4me2	 can	 occur	 even	 without	pharmacological	inhibition	of	LSD1		(Figure	13).											
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Figure	 13.	 	 Violin	 plot	 showing	 the	 degree	 of	 induction	 by	 the	 indicated	treatment	respect	to	control	(DMSO)	in	a.	class	1(n=	256),	c.	genes	induced	by	RA	high	and	co-treatment	(n=486)	e.	cotreatment-specific	genes	(n=382).	Boxplot	 shows	 level	 of	 H3K4me1	 (blue),	 H3K4me2	 (green),	 H3K4me3	(orange)	 and	 H3K27ac	 (purple)	 in	 regions	 LSD1	 positive	 and	 associated	 to	genes	 in	 b.	 class	 1(n=	 256),	 d.	 common	 genes	 between	 RA	 high	 and	 co-treatment	(n=486)	f.	cotreatment-specific	genes	(n=382)			
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	 We	 determined	 the	 chromatin	 alteration	 occurring	 in	 the	 subset	 of	 genes	specifically	 induced	 by	 the	 two	 treatments	 that	 trigger	 the	 cells	 to	differentiation:	 co-treatment	 specific	 genes	 (n=382)	 and	 genes	 induced	 by	both	RA	high	and	co-treatment	(n=486).	Not	surprisingly	active	transcription	is	 positively	 correlated	 with	 the	 presence	 of	 both	 H3K4me3	 and	 H3K27ac;	LSD1	 inhibition	 as	 expected	 induces	 an	 increase	 in	 the	 levels	 of	 H3K4me2	both	alone	and	to	a	greater	extent	 in	combination	with	RA	 low.	Remarkably	the	H3K4me2	marker	 increases	not	only	after	LSD1	 inhibition	but	also	after	high	doses	of	retinoic	acid	in	genes	regulated	by	RA	high	as	well	as	those	not	induced	by	RA	high	treatment.		The	results	of	 these	new	analyzes	show	hat	 the	 increase	 in	H3K4me2	 is	not	directly	 related	 to	 the	 activity	 of	 the	 inhibitor	 neither	 to	 transcriptional	activation,	 and	 therefore	 our	 initial	 hypothesis	 cannot	 be	 entirely	 correct.	While	the	lack	of	association	with	LSD1	inhibition	by	drugs	could	be	explained	by	 models	 where	 the	 enzymatic	 activity	 of	 LSD1	 can	 be	 reverted	 by	recruitment	 of	 other	 factors	 (with	 an	 unknown	 effect	 on	 chromatin),	 it	 is	more	 difficult	 to	 reconcile	 the	 lack	 of	 transcriptional	 activation	 in	 the	condition	 “RA	 high”	 with	 a	 positive	 role	 for	 H3K4Me2	 in	 gene	 activation,	though	 we	 cannot	 exclude	 that	 other	 unknown	 histone	 marks/other	mechanisms	may	 “block”	 the	positive	 effect	 	 and	only	upon	LSD1	 inhibition	we	can	achieve	full	transcriptional	activity.	One	alternative	and	somewhat	unexpected	explanation	for	what	we	observed	is	however	that	the	enhancement	of	H3K4Me2	(even	upon	LSD1	inhibition)	is	not	strictly	necessary	for	gene	activation.	To	assess	if	LSD1	enzymatic	activity	
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is	 required	 for	 the	 sensitization	 that	we	observe	 in	APL	 cells	 to	RA	 low,	we	expressed	either	wild	type	or	catalytic	inactive	LSD1	(K661A)	in	LSD1	knock	out	NB4	cells	(figure	14a)	 .	While	KO	cells	are	very	sensitive	to	low	doses	of	retinoic	 acid	 in	 terms	 of	 cell	 proliferation,	 LSD1	 expressing	 cells	 as	well	 as	K661A	 expressing	 cells	 are	 insensitive	 to	 RA	 low,	 recapitulating	 the	phenotype	of	NB4	wild-type	 cells	 and	 clearly	demonstrate	 that	 the	 catalytic	activity	of	LSD1	is	dispensable	for	the	sensitization	of	APL	cells	to	low	doses	of	retinoic	acid	(figure	14b).		In	addiction	by	ChIP-qPCR	we	demonstrate	that	both	re-expressed	wild-type	LSD1	 and	 mutant	 K661A	 are	 able	 to	 re-localize	 in	 the	 chromatin	 regions	bounded	 by	 LSD1	 and	 previously	 identified.	 And	 also	 that	 only	 wild-type	LSD1,	but	not	 the	 catalytically	 inactive	K661A,	 is	 able	 to	 reduce	 the	 level	 of	H3K4me2	in	that	target	regions	(Figure	14c).			
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Figure	14.	LSD1	catalytic	activity	is	dispensable	for	the	sensitization	of	
NB4	cells	 to	RA.	a.	Design	of	the	experiment.	NB4	LSD1	knock	out	cells	are	infected	with	LSD1	wild	type	or	catalytic	mutant	(K661A),	sorted	and	treated	with	RA.	b.	Proliferation	of	 cells	 treated	as	 indicated.	c.	ChIP-qPCR	of	LSD1	(left)	and	H3K4me2	at	selected	regions	in	NB4	wild	type	and	knock	out	cells	infected	with	empty	vector	(control),	LSD1	wild	type	and	K661A.	
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		These	 unexpected	 observations	 opens	 a	 plenty	 of	 questions	 on	 the	mechanism	of	action	of	LSD1	and	on	his	altered	function	after	inhibition.		The	 well	 known	 role	 of	 LSD1	 as	 a	 member	 of	 many	 protein	 complexes	containing	 histone	 deacetylases	 and	 methyltransferases	 such	 as	 NURD	 and	COREST	suggests	that	LSD1	should	exerts	its	actions,	at	least	those	related	to	the	 observed	 phenotype	 in	 APL,	 more	 as	 a	 member	 and	 scaffold	 of	 these	complexes	than	as	a	single	enzyme.			This	hypothesis	is	supported	by	the	increase	in	the	binding	of	the	protein	that	we	observe	after	differentiation-related	treatment	(cotreatment	and	RAhigh),	which	is	to	a	lesser	extent	observable	also	after	inhibition	of	the	protein	alone	(figure	15).	
		
Figure	 15.	 LSD1	 chromatin	 occupancy	 increase	 after	 treatment	 with	
inhibitor,	RA	high	and	cotreatment.	a.	Number	of	enriched	regions	(peaks)	respect	to	input	present	at	indicated	treatment.	b.	Correlation	heatmap	using	occupancy	data.			
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APPENDIX	DISCUSSION	AND	PERSPECTIVES	
	In	 conclusion	 these	 data	 support	 the	 therapeutic	 implications	 of	 LSD1	 in	AMLs,	APL	in	particular,	as	LSD1	fulfill	a	pivotal	role	in	normal	and	malignant	hematopoiesis.	 We	 demonstrate	 that	 the	 enzymatic	 acitivity	 of	 LSD1	 is	dispensable	for	the	retinoic	acid	sensitization	of	APL.	This	unexpected	result	suggests	a	novel	role	of	LSD1	as	a	key	interactor	and	scaffold	of	multiprotein		complexes.	 Since	 it	 is	 well	 known	 that	 LSD1	 is	 a	 member	 of	 many	 protein	complexes	 containing	 histone	 deacetylases	 and	 methyltransferases	 and	 it’s	been	described	the	interaction	of	LSD1	with	many	different	partner	(e.g	PRC2,	MLL)	further	investigation	should	be	performed	for	the	identification	of		LSD1	interactors	 in	 these	 APL	 model,	 and	 the	 characterization	 of	 their	 function	related	to	the	observed	phenotype.							 			 			
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LIST	OF	ABBREVIATIONS				aa		 	 amino	acid	ac		 	 (es.	H3K27ac)	acetylated	residues	AML	 	 Acute	Myeloid	Leukemia	APL	 	 Acute	Promyelocytic	Leukemia	ATP	 	 Adenosine	Triphosphate	ATRA/RA	 All	trans	retinoic	acid	bp	 	 base	pairs	ChIP	 	 Chromatin	Immuno	Precipitation	DDP-10147	LSD1	inhibitor	DNMT	 DNA	methyltransferase	HAT	 	 Histone/lysine	acetyltransferases	HDAC	 Histone	deactylases	HSC	 	 Hematopoietic	stem	cell	Kb	 	 kilobase	LSD1		 lysine	specific	demethylases	MC	 	 LSD1	inhibitor	DDP-10147	me	 	 (es.	H3K4me3)	methylated	residues	mRNA	 messanger	RNA	PCR	 	 Polymerase	chain	reaction	PML	 	 Promyelocitic	leukemia	protein	PML-RAR	 Acute	promyelocitic	leukemia	fusion	protein	PMTs	 post	translational	modifications	PR	 	 PML-RAR	protein	RA	low	 Physiological	concentration	of	RA	(0.01	μM)	RA	high	 Pharmacological	concentration	of	RA	(1	μM)	RARα	 Retinoic	acid	receptor			 	
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MATERIALS	AND	METHODS	
	
Pierluigi	 Rossi	 and	 Roberto	 Ravasio	 performed	 the	wet-lab	 experiments	 of	 the	project.		
Cell	culture	NB4	cells,	isolated	from	an	APL	patient	by	Lanotte	and	colleagues	(Lanotte	et	al.,	1999),	 have	 characteristics	 similar	 to	 APL	 blasts	 and	 were	 grown	 in	 RPMI	medium	 	 plus	 10%	 of	 fetal	 calf	 serum,	 2mM	 glutammine	 and	 1%	Penicillin/Streptomycin.		
Treatments	NB4	cells,	 plated	at	100.000/ml,	were	 treated	with:	dimethyl	 sulfoxide	 (DMSO)	1/1000;	 	 inhibitor	 ,2 µM,	 for	 6,12,24	 or	 96h;	 RAlow,	 0.01	 µM,	 for	 24	 or	 96h;		RAhigh	1	µM		for	24	or	96h.	 	
NB4	LSD1	KO	Single-guide	sequence	specific	to	LSD1	(exon	1)	was	designed	using	the	CRISPR	design	 tool	 (http://tools.genome-engineering.org,	 Ran	 et	 al.,	 2013)	 and	 cloned	into	 lentiCRISPR	 (Sanjane	 et	 al.,2014).	 The	 sequence	 selected	 (based	 on	 the	lowest	 number	 of	 predicted	 off-target	 in	 exon	 and	 the	 highest	 predicted	efficiency)	was	 the	 following	 one:	 5’-CACCGCGCGGAGGCTCTTTCTTGCG-3’.	 After	infection	cells	were	selected	with	puromycine	for	3	days	and	then	seeded	in	96-
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well	plated	by	dilution	and	expanded.	Clones	were	screening	using	Suveyor	Assay	(Ran	 et	 al.,	 2013)	 and	western	 blot	 analysis.	 Positive	 clones	were	 subjected	 to	Sanger	Sequencing.		Figure	9a:	NB4	cells	were	plated	at	3500	cells	per	well	 in	96	well	tissue	culture	dishes.	 Relative	 cells	 numbers	were	 assessed	 by	 Cell	 Titer-Glo	 luminescent	 cell	viability	 assay	 (Promega,	 Madison,	 WI	 USA).	 GraphPad	 6	 (GraphPad	 Software,	Inc.,	La	Jolla,	CA	USA)	was	used	for	curve	fitting.	Figure	9b:	Colony	 forming	ability,	 scored	after	7	days,	of	250	NB4	and	NB4	KO	cells	 plated	 in	 methylcellulose	 medium.	 Mean	 and	 standard	 deviation	 of	 three	independent	experiments	are	show.			
Gene	expression	analysis	mRNA-seq	 was	 performed	 according	 to	 the	 True-seq	 Low	 sample	 protocol	selecting	only	polyadenylated	 transcript.	RNA-seq	analysis	was	performed	with	the	 TopHat	 and	 Cufflinks	 algorithm	 (Trapnell	 et	 al.,	 2010).	 We	 adopt	 a	 36	 bp	paired	end	sequencing	strategy.	The	number	of	reads	obtained	was	comparable	among	the	samples.	The	values	considered	to	quantify	the	relative	expression	of	a	given	 gene	 correspond	 to	 the	 number	 of	 reads	 aligned	 per	 kilobases	 of	 the	transcript	per	million	mappable	fragment	detected	(FPKM,	fragment	per	kilobase	of	 exon	 per	 million	 fragments	 mapped).	 These	 values	 were	 used	 for	 all	 the	comparative	analysis.		The	threshold	set	to	consider	a	gene	as	being	regulated	was	FDR≤	0.05,	FPKM	≥	0.5	and	Fold	change	respect	DMSO	greater	than	absolute	Log2(1.5)	.	Class	in	table	1	are	mutually	exclusive,	genes	were	considered	up-regulated	(one	arrow)	if	they	fulfill	the	threshold	set	above,	while	the	further-upregulated	genes	
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(two	arrow)	were	genes	up-regulated	 in	both	 the	 treatments	but	with	a	 log2FC	greater	than	1.5	between	them.		Gene	 ontology	was	 performed	 through	 the	 use	 of	 QIAGEN’s	 Ingenuity	 Pathway	Analysis	(IPA,	QIAGEN	Redwood	City,	www.qiagen.com/ingenuity)	
	
ChIP-seq	analysis	Raw	data	corresponding	to	reads	coming	from	Illumina	Genome	Analyzer	II	were	analyzed	 according	 to	 the	 Fish	 the	 ChIPs	 pipeline	 (Barozzi	 et	 al.,	 2011).	 Reads	were	 mapped	 to	 Human	 NCBI36/hg18.	 Only	 sequences	 showing	 unique	alignment	 were	 used	 for	 peak	 detection,	 allowing	 for	 a	 maximum	 of	 two	mismatches.		Peaks	calling	was	performed	with	MACS	with	the	threshold	of	-log10(p)=5	for	all	the	 ChIP-seq	 except	 LSD1,	 for	 which	 we	 perform	 qPCR-ChIP	 and	 set	 a	 more	stringent	 threshold.	 	 For	 the	 validation	 of	 LSD1	 positive	 regions	 we	 selected	regions	 with	 several	 p-values	 (obtained	 with	 MACS	 peak	 calling)	 and	 perform	ChIP-qPCR	 assay	 in	 three	 independent	 experiments.	 Using	 intergenic	 region	negative	 for	 LSD1	 as	 control	 and	 anti-IgG	 antibody	 as	mock	 control	we	 set	 the	minimum	 value	 for	 positive	 true	 enrichment	 as	 the	 enrichment	 of	 negative	control	 plus	 three	 times	 the	 relative	 SD.	 26	 out	 of	 30	 regions	 tested	 were	considered	as	validated	and	thus	we	set	as	MACS	score	threshold	the	minimum	score	 among	 these	 26	 validated	 regions.	 With	 this	 new	 threshold	 of	 	 -log10(p)=16.9	we	 obtained	 15187	 LSD1	 peaks.	 	 Reads	 from	 each	 sample	were	normalized	 to	 the	 input	 of	 NB4	 cell	 line.	 Peaks	 were	 associated	 to	 Refseq	annotated	genes	according	to	GIN	(Cesaroni	et	al.,	2008)	while	intergenic	regions	were	considered	as	having	more	than	22kb	of	distance	from	the	nearest	gene.		
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For	LSD1	ChIP-seq	after	treatment	we	used	the	same	validation	strategy	and	set	the	thresholds	to	−10*log10(pvalue)= 357,239,196	MACS	score	respectively	 for	LSD1	inhibitor,	cotreatment	and	RAhigh.	
UCSC	 Genome	 tracks	 were	 generated	 normalizing	 each	 sample	 to	 the	 same	sequencing	depth.		The	 intersection	 among	 the	 peaks	 datasets	 was	 performed	 with	 bedtools	intersect	tool,	peaks	are	considered	overlapping	if	they	share	at	least	1bp.	Reads	coverage	for	the	comparison	of	chromatin	changes	in	the	first	three	classes	of	 gene	 expression	 (Table	 1)	 was	 performed	 with	 bedtools	 suite	 inside	 the	window	 delimitated	 by	 the	 LSD1	 peaks	 associated	 to	 each	 gene;	 differences	 in	methylation,	acetylation	or	gene	expression	values,	as	FPKM,	among	the	different	treatments	were	estimated	by	means	of	Repeated	Measures	ANOVA	followed	by	Tukey's	Multiple	Comparison	Test.			All	plots	were	performed	with	R	(R	Core	Team,	2016).		Vioplot:	 Daniel	 Adler	 (2005).	 vioplot:	 Violin	 plot.	 R	 package	 version	 0.2.	http://wsopuppenkiste.wiso.uni-goettingen.de/~dadler	Pheatmap:	Raivo	Kolde	 (2015).	 pheatmap:	Pretty	Heatmaps.	R	package	 version	1.0.8.	https://CRAN.R-project.org/package=pheatmap	DiffBind:		Stark	R	and	Brown	G	(2011).	DiffBind:	differential	binding	analysis	of	
ChIP-Seq	peak	data.				 	
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Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating gene expression, and behave as
oncogenes in several cancer types, spurring the development of HDAC inhibitors (HDACi) as anticancer drugs. This review
discusses new results regarding the role of HDACs in cancer and the effect of HDACi on tumour cells, focusing on haematological
malignancies, particularly acute myeloid leukaemia. Histone deacetylases may have opposite roles at different stages of tumour
progression and in different tumour cell sub-populations (cancer stem cells), highlighting the importance of investigating these
aspects for further improving the clinical use of HDACi in treating cancer.
Epigenetic mechanisms have a key role in the control of biological
processes, and chromatin alterations may lead to the onset and
progression of many diseases, first of all cancer.
Unlike genetic alterations, epigenetic alterations are generally
reversible. For this reason, drugs acting against epigenetic targets
(epidrugs) have been developed and some of them have been
approved for selected cancer indications, thus validating the
concept of epigenetic therapy.
Histones present a great number of modifications, including
acetylation, methylation, phosphorylation, ubiquitination and
many others, more recently identified. This pattern is sometimes
referred as ‘histone code’, but the parallelism with a code
represents an oversimplification, as similar combinations of
histone marks may result in different functional outcomes
depending on the context, and different combinations may lead
to a similar functional result.
Among histone modifications, lysine acetylation depends on the
antagonistic activity of two enzyme classes: histone acetylases
(HATs) and histone deacetylases (HDACs, subject of this review).
The human HDAC family comprises 18 proteins that can be
grouped into four classes on the basis of sequence homology with
yeast proteins:
 Class I (HDAC 1-2-3-8) are homologous to the yeast Rpd3,
localise in the nucleus and contain a single deacetylase domain at
the N terminus.
 Class II HDACs can be further divided into two classes: IIa
(HDAC 4-5-7-9, localised in the nucleus and cytoplasm) and IIb
(HDAC 6 and 10); HDAC6 is mainly located in the cytoplasm
and contains two catalytic domains, whereas HDAC10 contains
a functional N-terminal domain and a C-terminal incomplete
domain.
 Class III HDACs are also termed sirtuins (SIRT1–SIRT7), which
are homologs of yeast Sirt2 and differ structurally from the other
classes, requiring NADþ as a cofactor.
 Class IV contains a single HDAC (HDAC11) with a catalytic
domain shared with classes I/II HDACs.
Here, we will focus on Classes I/II and IV HDACs. These
HDACs mediate their function as part of large macromolecular
complexes in association with other factors: HDAC1 and HDAC2
are found in the mSin3A, NURD and Co-REST complexes, and
HDAC3 is found associated with N-CoR and SMRT, whereas
several proteins involved in the ubiquitin pathway are found
associated with HDAC6 (Minucci and Pelicci, 2006).
HDACS AND THE CONTROL OF HISTONE (AND NON-
HISTONE) ACETYLATION
The addition of acetyl groups to lysine residues in the histone tails
by HATs is responsible for a relaxed and accessible chromatin
structure, and is associated with transcriptional activation;
conversely, HDACs remove acetyl groups and lead to a more
closed chromatin structure, generally associated with transcrip-
tional repression.
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Genome-wide studies of HDACs by chromatin immunopreci-
pitation followed by next-generation sequencing (Chip-Seq)
revealed, however, a strong association between HDACs and
active genes, and suggested a role for HDACs also in active
transcription: when associated with active genes, HDACs act to
remove acetyl groups added by HATs during transcriptional
initiation and elongation, providing a reset of the chromatin
structure that is required for a second round of transcription.
Indeed, excessive histone acetylation at transcribed regions
could ‘destabilise’ chromatin, thus leading to an increase of
transcription at erroneous starting sites (Wang et al, 2009). In
Drosophila, the UpSET complex—that includes HDACs—is
required to reduce spreading of histone acetylation from active
promoter regions and therefore limiting transcriptional noise
(Rincon-Arano et al, 2012). The canonical relationship between
HDACs, low levels of histone acetylation and transcriptional
repression is therefore not always valid.
Histone acetylases and HDACs are responsible for the reversible
acetylation not only of histones but also of a large number of
additional substrates such as transcription factors, DNA repair
enzymes and nuclear and cytoplasmic proteins. Not all protein
acetylation, however, necessarily derives from the enzymatic action
of HATs/HDACs: protein acetylation in mitochondria may be a
chemical event facilitated by the alkaline pH and high concentra-
tions of reactive acetyl-CoAs present in the mitochondrial matrix
(Wagner and Payne, 2013).
Acetylation of non-histone proteins and regulation of their
function adds another layer of complexity to the action of HATs/
HDACs: importantly, this also precludes from considering HDACs
as purely ‘epigenetic factors’ (Minucci and Pelicci, 2006).
Proteomic studies have very recently led to the discovery of a
large number of novel histone post-translational modifications
(PTMs) that show additional acyl moieties beside acetylation
(Kebede et al, 2015); among those PTMs, propionylation,
butyrylation, crotonylation, succinylation, malonylation, glutaryla-
tion and lysine 2-hydroxyisobutyrylation share the use of short-
chain acyl-coAs derived from energy metabolism as cosubstrate(s).
These histone PTMs contribute to transcriptional regulation by
promoting DNA unwrapping and nucleosome disassembly,
reducing nucleosome stability and influencing the action of
chromatin-associated factors: intriguingly, HDACs are able to
remove at least a subset of these newly discovered acyl-histone
marks (Kebede et al, 2015).
Currently, it remains unclear whether concentration of coAs
(depending on the metabolic status of the cell) could be a critical
factor determining the type of histone acylation, and if HDACs
could have a role in transmitting metabolic signals by modulating
the chromatin structure (a function already known for class III
HDACs, regulated by NADþ /NADH ratio) and which impact
metabolism can have on histone modifications. Importantly,
tumour cells show constant alterations in metabolism that may
lead, therefore, to alterations in HDAC function, as recent studies
begin to suggest (Chiaradonna et al, 2015).
HDACS IN CANCER AND A (WEAK) RATIONALE FOR THE
DEVELOPMENT OF HDAC INHIBITORS
Given their pleiotropic roles and their involvement in essentially all
cell functions, HDACs may not be considered at a first glance as
attractive targets for therapy, owing to the likely interference of
HDAC inhibitors with several processes occurring in normal cells
and therefore high risk of side effects. Indeed, the first HDAC
inhibitors were initially characterised for their antitumour activity
in vitro before the discovery that they were known to inhibit
HDACs: their use in preclinical models (in vitro and in vivo)
showed a significant therapeutic window, with reduced effects on
normal cells.
The discovery of the potent antitumoral effects following HDAC
inhibition led to the hypothesis that HDACs themselves may act as
oncogenes, and, in fact, distinct HDACs are found overexpressed
in various solid tumours, in some cases showing a differential
expression in tumour subtypes: as an example, HDAC1 is highly
expressed in hormone receptor-positive breast cancer, whereas
HDAC2 and HDAC3 are more expressed in breast cancers with a
more aggressive phenotype including hormone receptor-negative
cancers (Mu¨ller et al, 2013). It is difficult, however, to correlate the
degree of expression of individual HDACs with particular
functional consequences and biological phenotypes: loss of
acetylation of lysine 16 and 20 of histone H4 has been observed
in various cancer cell lines and primary tumours, and described
as a hallmark of human cancer: this could be because of
overexpression of the class III HDAC SIRT1, which is capable of
deacetylating histone H4K16 (Fraga et al, 2005). Reduced
acetylation because of enhanced expression of HDACs may lead
to transcriptional repression of tumour-suppressive pathways,
including cell cycle regulators and DNA repair pathways. Over-
expression of HDACs has been linked (together with other histone
modifications) to the epigenetic repression of the locus encoding
for the tumour suppressor CDKN1A, and of DNA damage repair
genes such as BRCA1 and ATR (Eot-Houllier et al, 2009), but the
consequence of HDAC overexpression may also impact on
non-histone substrates: HDAC1 and HDAC2 regulate acetylation
of the oncosuppressor p53, thus inhibiting its function (Insinga
et al, 2004).
Overexpression of HDACs has been proposed in several cases as
a negative prognostic marker, independently of tumour type and
disease progression; however, this is not always the case as high
levels of HDAC6 predict better prognosis in ER-positive breast
cancer (Saji et al, 2005), or in CTCL.
Although HAT encoding genes are found frequently mutated or
amplified in cancer, with consequent loss or alteration of function,
there are reports of only rare, inactivating mutations of HDACs in
cancer, which may suggest oncosuppressive roles for HDACs
(Ropero et al, 2006).
We performed a preliminary analysis of the mutational
landscape of HDACs using available data sets, focusing on
missense mutations in the coding sequence, without further
investigating the mutational impact of each mutation (Figure 1
and Supplementary Table S1).
The frequency of missense mutations of HDACs varies greatly
in different human cancers: although in some cases (melanoma,
lung cancer) the high frequency of mutations (close to 30%
considering all HDACs) is somewhat expected because of the
general high mutation rate caused by exposure to carcinogens
(sunlight, smoke), other cancer types show a rate of HDAC
mutations that could only in part be explained by their general
mutational trend. In general, class II HDACs show higher
percentages of mutations, and the distribution of missense
mutations in the two most mutated HDACs, HDAC4 and HDAC9,
show that although most mutations are distributed along the entire
coding sequence, and therefore they are unlikely to be functionally
relevant, a few sites – located in the catalytic domain – mutated in
a higher number of patients exist, suggesting a potential alteration
of the enzyme function (Figure 1B).
Taken together, these observations (that need to be extended)
hint that just looking at mutations and/or altered expression
pattern will not provide frequently a conclusive answer, and that
more in-depth mechanistical insights are required to understand
the altered function of HDACs in cancer cells.
Indeed, HDAC inhibition affects markedly cancer cells,
inducing (depending on drug, dosage and tumour cell type) cell
cycle arrest, differentiation, induction of cell death, reduction of
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angiogenesis and modulation of the immune system. An
‘epigenetic vulnerability’ of tumour cells has been proposed, where
– in contrast to normal cells that show redundancy in epigenetic
regulatory mechanisms – HDACs may be essential in tumour cells
for the maintenance of a set of key genes required for survival and
growth (Dawson and Kouzarides, 2012).
A large number of HDAC inhibitors has been synthesised and
tested in clinical trials, resulting in the approval of four inhibitors
(Vorinostat, Romidepsin, Bellinostat, Panobinostat: a list of HDAC
inhibitors, their classification and clinical status is provided in
Table 1). This could be interpreted as a successful history of drug
development, with validation of HDACs as important targets in
cancer, but the situation is far more complex, and the clinical
results do not reflect those expected from the preclinical work,
both in terms of efficacy (observed only in selected cancer
subtypes, mainly in haematology) and safety (several side
effects were observed, among which the most common are
fatigue, diarrhoea, bone marrow toxicity, thrombocytopenia;
Subramanian et al, 2010). The reasons for this, at least in
part, disappointing set of clinical results are not clear; one
explanation could be the lack of selectivity of most of the HDAC
inhibitors tested clinically and approved to date, acting as
paninhibitors on all HDAC classes (not including sirtuins): the
global inhibition of several non-redundant HDACs, with
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partially overlapping but with clearly distinct and sometimes
contrasting functions, may result in a difficult to predict
phenotype, and subtle differences among species may explain the
different results observed in murine models.
Indeed, knockout studies in mice on all members of class I
HDACs demonstrated the unique roles of each HDAC in the
control of specific gene expression programmes: HDAC1-null mice
die at day E10.5 and display severe proliferation defects and
general growth retardation; HDAC2-null mice die 24 h after birth
for cardiac malformations; HDAC3-null mice die before E9.5 for
defects in gastrulation probably because of defective DNA repair
(Haberland et al, 2009; Yang and Seto, 2008).
The hypothesis that inhibition of specific HDACs may have a
better therapeutic outcome will be put to test once we will evaluate
more selective HDAC inhibitors in clinical trials (that is supposed
to happen soon).
HDACS IN APL: DISTINCT ROLES IN SPACE AND IN TIME
In contrast to solid tumours, we have a better understanding of the
altered function of HDACs in haematological malignancies.
Here, a revisitation of recent results, mainly focusing on acute
myeloid leukaemia (AML) models, lead us to additional reasons to
explain the complexity of the use of HDAC inhibitors in the
clinical setting, linked to distinct effects of HDACs at different
stages of tumourigenesis and different action of HDAC inhibitors
in distinct tumour cell subtypes.
Acute promyelocytic leukaemia (APL) was one of the first
diseases in which the involvement of HDACs was demonstrated
mechanistically. Acute promyelocytic leukaemia is characterised by
the block of myeloid differentiation at the promyelocytic stage, and
is associated with the chromosomal translocation t(15;17), to
generate the PML-RAR fusion protein of retinoic acid receptor-a
(RAR) with the promyelocytic leukaemia protein (PML). Retinoic
acid (RA) showed clinical efficacy in APL patients before the
demonstration that it acted by direct targeting of the oncogenic
fusion protein (Minucci and Pelicci, 2006).
Subsequent molecular studies placed RA treatment of APL
among the best characterised examples of both ‘transcription
therapy’ (whereby the drug targets specifically the oncogenic
transcription factor and its aberrant action) and ‘differentiation
therapy’, which reprograms leukaemic cells for terminal
differentiation (Tallman et al, 1997; Huang et al, 1988). For all
these reasons, although it is a rare disease, APL has been for several
years an important model system for learning lessons that can be
potentially expanded to other forms of cancer.
In normal cells, RAR acts as a transcription factor, regulating
myeloid differentiation and binding in a heterodimeric form
with the retinoid X receptor-specific DNA sequences (called
RA-responsive element) found at RAR target genes. In the absence
of RA, RAR is found in association with HDAC-containing
complexes and represses transcription: RA leads to a conforma-
tional switch that causes the release of the corepressor complexes
and binding of transcriptional coactivators, with consequent
transcription of RAR target genes.
In APL cells, physiological concentrations of RA do not result in
the release of HDAC–corepressor complexes from PML-RAR,
leading to altered regulation of RAR target genes and of additional
PML-RAR-specific targets, and subsequent differentiation block
(Minucci and Pelicci, 2006), whereas pharmacological doses of RA
(10- to 100-fold higher than physiological concentrations) reverse
the action of the fusion protein, owing to induction of its
degradation, and lead to reactivation of the differentiation
programme of APL cells. In patients, however, treatment with
RA leads only to a transient remission of the disease but cannot
entail a definitive cure unless RA is combined to other drugs such
as chemotherapy or arsenic.
Studies conducted in transgenic mice have demonstrated that
the presence of PML-RAR alone is not sufficient by itself to confer
full leukaemic potential to haematopoietic cells, and second hits are
necessary for leukaemia development; this thus defines
a preleukaemic phase where PML-RAR is acting initially,
molecularly distinct from the clonal leukaemia that develops at a
later stage.
HDACs in time. The model depicted before suggests a critical role
for HDACs in APL, as they are required for the fusion protein to
arrest leukaemic differentiation, but new results however have
shown that the role of HDACs in APL is more complex than
previously thought and demonstrated a dual role for HDACs
dependent on the stage of disease progression (so changing ‘in
time’).
Indeed, mice transplanted with haematopoietic progenitors
derived from PML-RAR transgenic mice, and carrying knockdown
of either HDAC1 or HDAC2, showed a strongly reduced
preleukaemic phase, with accelerated leukaemia development
Table 1. HDAC inhibitors classified according to: (a) status of clinical advancement; (b) HDAC(s) targeted and (c) chemical class
Compounds Target Class Highest phase trial
Panobinostat (LBH-589) Pan-HDAC inhibitor Hydroxamic acids Approved in 2015 for multiple myeloma
Belinostat (PXD101) Pan-HDAC inhibitor Hydroxamic acids Approved in 2014 for PTCL
Romidepsin (desipeptide-FK228) Pan-HDAC inhibitor Cyclic tetrapeptides Approved in 2009 for CTCL
SAHA(Vorinistat, Zolinza) Pan-HDAC inhibitor Hydroxamic acids Approved in 2006 for CTCL
Valproic acid Pan-HDAC inhibitor Short-chain fatty acids Phase III
Tacedinaline (CI994) Subclass I-selective inhibitor (HDACs 1, 2 and 3) Benzamides Phase III
Givinostat (ITF2357) Pan-HDAC inhibitor Hydroxamic acids Phase II
Resminostat (4SC201) Pan-HDAC inhibitor Hydroxamic acids Phase II
Abexinostat (PCI24781) Pan-HDAC inhibitor Hydroxamic acids Phase II
Rocilinostat (ACY1215) Selective class II HDAC inhibitor Hydroxamic acids Phase II
Quisinostat (JNJ-26481585) Pan-HDAC inhibitor Hydroxamic acids Phase II
Practinostat (SB939) Inhibit class I, II and IV HDACs Hydroxamic acids Phase II
Mocetinostat (MGCD0103) Specific against class I and IV HDACs Benzamides Phase II
Entinostat (MS275-SNDX-275) Class I HDAC inhibitor Benzamides Phase II
Sodium phenylbutyrate Inhibit class I and II HDACs Short-chain fatty acids Phase II
AR42 Pan-HDAC inhibitor Hydroxamic acids Phase I
4SC202 Selective class I HDAC inhibitor Benzamides Phase I
Pyroxamide (NSC696085) Inhibitor of affinity-purified HDAC1 Hydroxamic acids Phase I
CHR-3996 Selective class I HDAC inhibitor Hydroxamic acids Phase I
CHR-2845 Hydroxamic acids Phase I
Abbreviations: CTCL¼ cutaneous T-cell lymphoma; HDAC¼ histone deacetylase; PTCL¼peripheral T-cell lymphoma. Adapted from Valente and Mai (2014), http://www.fda.gov/default.htm.
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(Figure 2A). Interestingly, HDAC1/2 knockdown caused right after
transplantation a marked increase in cells (GþKþ ) characterised
by coexpression of differentiation markers (GR1) and more
immature markers (C-kit). This cell sub-population in the absence
of HDAC knockdown is found markedly expanded in the
leukaemic stage, and is enriched in leukaemia-initiating cells
(LICs: see below). Treating mice in the preleukaemic phase with
the HDAC inhibitor (HDACi) valproic acid (VPA) mimicked the
effect of HDAC1/2 knockdowns.
These results are in striking contrast with those obtained in the
leukaemic phase, where knockdown of the same HDACs
caused differentiation and apoptosis of APL cells, leading to
prolonged mice survival (Figure 2B). Valproic acid treatment
induces selectively in leukaemic cell differentiation followed by
apoptosis because of the activation of the death receptor pathway.
Taken together, these results imply a dual role of HDAC1 and
HDAC2 in APL initiation and maintenance, and suggest that they
may act as oncosuppressors in the preleukaemic phase, and as
oncogenes in leukaemia (Santoro et al, 2013) (Figure 2). Interest-
ingly, HDAC1/HDAC2 knockdown or knockout accelerated
development of other tumour types (lymphomas and skin
tumours), suggesting that this oncosuppressive role may be more
general (Winter et al, 2013).
Not all HDACs share this dual, time-dependent function:
HDAC3 acts as an oncogene also during the preleukaemic phase,
and its knockdown or inhibition by selective drugs leads to cell
differentiation and enhanced apoptosis, and lack of leukaemia
development (Matthews et al, 2015).
Several questions remain unanswered: (I) How do HDAC1/
HDAC2 contribute to decrease in the oncogenic potential of PML-
RAR-expressing cells in preleukaemia? (II) Is HDAC1/2 loss a
second hit sufficient to transform cells, or further hits are required?
(III) Most importantly, as HDACs may have an oncosuppressive
function, does this imply that clinical treatment with HDACi (such
as selective HDAC1i/HDAC2i from those studies discussed above)
may favour secondary cancers?
HDACs in space. Most cancers are heterogeneous, and the
continuous expansion of the tumour mass is sustained by the
self-renewing properties of a sub-population termed ‘cancer stem
cells’ (CSCs) (in leukaemia CSCs are also called LICs) (Kreso and
Dick, 2014). The inability of existing therapies (such as
chemotherapy) to eradicate CSCs, and to act mainly on the bulk
of the tumour mass (that does not proliferate indefinitely) is
thought to be one of the most relevant causes for recurrence.
Experimental protocols have been set up to measure LICs, based
on limiting transplantation experiments in recipient mice of
leukaemic cells and recent studies have started to explore the effect
of HDACi on different tumour sub-populations in APL.
Valproic acid treatment of APL mice extend their survival, but
shortly after interruption of treatment the disease relapses, leading
to death; studies to measure the effect of VPA on LICs showed that
the number of LICs was not affected by the treatment, consistently
with the observed relapse. Valproic acid was therefore selectively
acting on the bulk of leukaemic blasts, pushing their differentiation
and apoptosis without affecting the self-renewal potential of LICs
(Leiva et al, 2012) (Figure 3, upper panel). It remains to be seen if
HDACi with different specificities show a different behaviour, and
whether genetic experiments (knockdown) will be consistent with
the pharmacological observations. We speculate that other HDACs
and HDAC-containing complexes not tackled by VPA are essential
for LIC maintenance, and therefore HDACs may act differentially
in specific tumour cell sub-populations (different tumour ‘space’).
If we analyse the effect of other drugs on LICs used in APL
patients, arsenic treatment was shown to act strongly on LICs
(Figure 3, middle panel), and RA showed a dose-dependent
phenotype, being more effective on bulk cells at lower doses (Nasr
et al, 2008).
It will be of great interest to test in preclinical models the
combination of VPA with drugs acting on LICs (such as arsenic
trioxide): VPA alone cannot eliminate the disease as it is not
targeting LICs, but targeting LICs alone may not necessarily work,
as bulk tumour cells can still contribute significantly in the short
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Leukaemic cells
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Figure 2. A time-dependent role for HDACs in leukaemia
development. (A) During the preleukaemic phase of APL, HDAC1/2 act
as tumour suppressors, and their knockdown results in accelerated
leukaemia development. This can be because of higher frequency of
additional hits, or to direct transformation of PML-RAR preleukaemic
cells. (B) During the leukaemic phase, knockdown of HDAC1/2 cause
differentiation and then apoptosis of APL cells, with an extended
lifespan of the leukaemic mice.
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Figure 3. Histone deacetylase inhibitors have distinct effects on
tumour cell sub-populations. (Upper panel) Histone deacetylase
inhibition by VPA treatment of APL mice results in differentiation of
bulk leukaemic cells and prolonged survival, but as LICs are not
targeted disease recurs. (Middle panel) Treatment with arsenic leads to
tumour regression because of significant reduction in the number of
LICs, and progressive tumour exhaustion, but tumour growth in the
short term may continue because of bulk of leukaemic cells and – in
high-risk aggressive disease forms – lead to patient death. (Bottom
panel) Combining the two treatments, by acting on both tumour cell
sub-populations, may offer the best perspective in terms of disease
control and LIC eradication.
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term to tumour growth, leading to patient death before the effect of
LIC clearance can be appreciated clinically. Only the combined
targeting of the entire tumour cell mass (LICs and bulk) could lead
to disease eradication effectively and rapidly, and represents the
best potential for cure (Figure 3, bottom panel).
CONCLUSIONS
Pan-HDACi have given favourable results in a small set of patients
with selected haematological diseases, but their use in mono-
therapy has not been satisfactory. The difference in sensitivity to
HDACi cannot be easily allocated to a single cause, making it
difficult to envision a smart approach to patient stratification.
However, we believe that despite the disappointing results, this
field deserves further study and remains a promising therapeutic
avenue. Soon, we will know whether more selective HDACi will be
more effective in the clinics, and with reduced side effects. The
studies in murine models of leukaemia suggest that it is necessary
to consider not only the differences among different classes of
HDACs but also how the same molecules may act in ‘time’ and
‘space’, as we have previously illustrated. In particular, we propose
that a systematic effort should be performed to study the effects of
HDACi and other epidrugs on the stem cell compartment vs the
rest of tumour cells, to devise treatment schemes that combine
more efficiently drugs targeting the different tumour cell sub-
populations. Of course, this must not be limited to epidrugs, and
combination with other agents such as DNA-damaging che-
motherapeutic drugs, or proteasome inhibitors, has already shown
promising results that could be reinterpreted based on the studies
proposed above. Histone deacetylase inhibitors may well find their
optimal ‘clinical space’ in the end.
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Self-renewal of tumor cells: epigenetic determinants
of the cancer stem cell phenotype
Roberto Ravasio1, Elena Ceccacci1,2 and Saverio Minucci1,2,3
Among the functional subpopulations that coexist within the
tumor, ‘cancer stem cells’ are characterized by increased self-
renewal and the ability to derive all of the other subpopulations of
tumor cells (‘bulk’). The functional heterogeneity among cancer
stem cells and bulk cells must reflect distinct cellular epigenetic
landscapes, but — due to the difficulty to isolate bona fide cancer
stem cells with a high degree of purity — those different
epigenetic landscapes, and the molecular mechanisms
underlying them, remain largely unknown. Cues of intratumor
phenotypic plasticity complicate the interpretation of the cancer
stem cell phenotype: we contend that, however, the concept of
cancer stem cell has crucial therapeutic implication, and remains
a key target for the exploration of the cancer epigenome.
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Introduction: the cancer stem cell phenotype
Cancer is characterized by extensive genetic and func-
tional heterogeneity. The progress of sequencing tech-
nologies allows now to appreciate the complex mutational
landscape of the tumor cell mass that consists of a large
number of genetically distinct subclones, progressively
evolving through Darwinian selection mechanisms both
intrinsic, and related to therapy [1]. The degree of genetic
complexity is somewhat unexpected, and bears daunting
implications in view of the potential approaches to cancer
therapy.
Long before these studies, however, differences in the
behavior of cancer cells that cannot be ascribed to genetic
mutations alone have been identified as an additional
source of heterogeneity. Here, in contrast to the hetero-
geneity observed in normal cells that follow ordered
developmental programs and respond to defined environ-
mental pressures, the functional heterogeneity of cancer
cells is assumed to be largely disordered and following
more self-autonomous, scarcely controlled regulatory
mechanisms.
Cancer stem cells (CSCs) are supposedly the cells within
the tumor cell mass that retain self-renewing capacity and
lie at the root of the hierarchy that defines the heteroge-
neity of all cells that comprise the tumor. Many authors
define CSCs on the basis of their functional ability to
initiate a tumor in a transplantation assay in mice (when
human tumor cells are used, the assay is performed in
immunocompromised mice). In many cases (leukemias,
breast, lung and colon cancer among the best studied), the
number of cells able to initiate a tumor (functional CSCs)
is small compared to the total number of tumor cells,
similarly to the normal stem cell compartment of most
tissues (<1% of total cells). However, in other cancer
types (such as melanoma) most of the cells are able to
initiate a tumor in those assays that implies that a distinct
CSC subpopulation does not exist. Additional studies
suggest that distinct subpopulations are characterized
by different grades of stemness, but technical hurdles
remain in the interpretation of these assays. A more in-
depth characterization of CSCs dynamics has revealed in
many cases clues of phenotypic plasticity, suggesting a
dynamic transition between a ‘CSC state’ and a ‘non-CSC
state’. Using a breast cancer inducible model of oncogen-
esis, in which putative CSCs can be sorted on the basis of
expression of the CD44 cell surface marker (CD44high as
compared to the non-CSCs that are CD44low), Iliopoulos
and colleagues showed that while — as expected — CSCs
are able to give rise to non-CSCs, there is also, though to a
lesser extent, reversion of non-CSCs to CSCs [2]. This
observation has been confirmed also in primary human
mammary breast cells [3]. According to these findings,
CSC and non-CSC do not represent distinct and stable
cell phenotypes, but functional subpopulations. Starting
from the observation that each isolated subpopulation is
able to generate the other subpopulation restoring the
dynamic equilibrium among the two functional states, a
Markov model of cell-state dynamics has been proposed
[4]: this model assumes that interconversion rates depend
on the cell current state, highlighting that intercellular
signals are not necessarily required for the equilibrium.
Whatever the exact nature of CSCs (functional state or
Available online at www.sciencedirect.com
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defined hierarchical component of the tumor), the transi-
tion from a CSC to a non-CSC cell/state must involve
epigenetic changes and an understanding of those
changes may be of critical relevance to identify distinct
molecular landscapes of tumor cells.
Epigenetic players recently involved in
controlling the cancer stem cell phenotype
In melanomas, Roesch and colleagues described the
presence of a slow cycling population characterized by
high expression levels of JARID1B, a member of the
family of Jumonji/ARID1 (JARID1) histone 3 lysine
4 (H3K4) demethylases [5]. JARID1B is not needed
for melanoma initiation, but it is essential for tumor
maintenance, both in vitro and in vivo, and for metastatic
progression. Consistent with the findings described
above, the phenotype of high expression of JARID1B
is dynamic, and cells expressing low levels of Jarid1B may
turn to high levels of expression. Dependence for high
JARID1B expression in these stem-like melanoma cells
support the idea that CSC and non-CSC cells/states are
characterized by distinct and dynamic epigenetic land-
scapes, and depend on distinct epigenetic players. This is
of capital importance, because it implies that we should
explore the role of epigenetic players in the CSC/non
CSC cell-states. JARID1B is overexpressed also in puta-
tive breast CSCs, suggesting a more general role of this
enzyme in controlling cancer stem cell phenotypes. In-
terestingly, in ER+ luminal breast cancer cells JARID1B
colocalizes with the nuclear protein CTCF, which might
modulate its histone demethylase activity and chromatin
binding. In these cells, knockdown of JARID1B has
growth-inhibitory effects [6].
JARID1B is also highly expressed in hematopoietic stem
and progenitor cells (HSPCs) and in many acute myeloid
leukemias (AMLs), but its role in controlling self-renewal
of murine AMLs is not consistent with the role identified
in human solid tumors [7,8]. Using a murine model of
AML induced by the MLL-AF10 oncogene, and in which
leukemic stem cells (LSCs) and non-LSCs are distin-
guished by the presence or absence of c-kit expression
respectively [9], Wong and colleagues report that H3K4
dimethylation and trimethylation levels are significantly
higher in LSCs (c-kit+) than non-LSCs (c-kit) [10].
Furthermore, JARID1B transcript levels in c-kit+ cells are
lower than c-kit and ectopic overexpression of JARID1B
markedly suppresses in vitro growth of MLL-leukemic
cells, but does not impact the growth of non-MLL
leukemias, suggesting a tumor suppressive role for JAR-
ID1B. It remains to be seen if this is a specific feature of
MLL-driven AMLs, harboring an alteration of the H3K4
methyltransferase activity of MLL that leads to a differ-
ent role of JARID1B. In contrast, Harris et al. report that
KDM1A, a flavin adenine dinucleotide (FAD)-depen-
dent demethylase with monomethyl and dimethyl
H3K4 and H3K9 substrate specificity, is overexpressed
in MLL-AF9 LSCs and drives their leukemogenic po-
tential, making KDM1A a potential therapeutic target in
MLL-driven leukemias [11]. The finding that two epige-
netic factors with a similar enzymatic function can have
opposing roles in the same disease (JARID1B and
KDM1A in MLL-driven leukemias) is not unique (see
the histone H3K27me3 demethylases JMJD3 and UTX
in T-cell acute lymphoblastic leukemia [12]), and is
strongly suggestive that specific (rather than global)
changes in chromatin states (and the histone/DNA mod-
ifications underlying them) are responsible for the ob-
served stem-cell phenotypes.
As reported in melanoma, a quiescent drug-tolerant sub-
population has been found in a non-small cell lung cancer
cell line (PC9) [13]. This subpopulation expresses CD133
and CD24, previously described markers of CSCs [14,15],
and is able to resume normal proliferation and to give rise
to CD133/CD24 cells once drug treatment is stopped.
Interestingly, these cells present high levels of JARID1A,
another member of the Jumonji/ARID1 H3K4 demethy-
lase family, and display reduced H3K4 trimethylation and
dimethylation levels [13].
Aberrant DNA-methylation of tumor cells: an
old player with new roles in cancer stem cell
functions
While aberrant roles of histone-modifying enzymes have
been studied more recently, abnormalities in DNA meth-
ylation in cancer cells were observed since 1980s [16–19]:
these abnormalities appear in the early phases of tumor
transformation, but their role in defining tumor heteroge-
neity has not been studied extensively [20,21]. Starting
from evidences of a cellular hierarchical organization in
AMLs and that LSC gene expression signatures are
predictive of clinical outcome in multiple cohorts of
AML patients [22], Jung and colleagues defined the
DNA methylation profile of LSCs (defined on their
engrafting ability in a xenotransplantation assays) and
their downstream non-engrafting blasts, identifying more
than 3000 differentially methylated regions (DMRs), of
which almost 92% are hypomethylated in LSCs [23].
Integrating DNA methylation with gene expression pro-
file, they identified a LSC epigenetic signature and
showed that genes involved in leukemogenesis and pro-
liferation of hematopoietic stem and progenitor cells
(HSPCs), such as REC8 and the HOXA cluster, are
hypomethylated and overexpressed in LSCs; moreover,
they demonstrated that human AMLs presenting the
LSC-like epigenetic signature are associated with a worse
clinical outcome compared to blast-like AMLs [23],
confirming the clinical prognostic potential of DNA-
methylation analysis of AML samples [24]. Similarly,
in the CSC signature of breast cancer cells, DMRs have
lower methylation levels in CSCs than in non-CSCs, and
tumors enriched in CSCs are associated with a decrease in
relapse-free survival [25].
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Alterations of chromatin states: bivalent
domains and phenotypic transitions of cancer
stem cells
Abnormal activity of pathways that control normal stem
cell self-renewal, embryonic development and differen-
tiation, such as WNT, SHH and NOTCH, have been
found in CSCs. As these pathways are active both in
normal and cancer stem cells, the difference between a
normal and a malignant cell must lie in the mechanisms
(including epigenetic alterations) that regulate those
pathways. Importantly, it has been shown that in normal
(both embryonic and adult) stem cells, promoters of many
differentiation-related genes are characterized by the
simultaneous presence of both active (H3K4me3) and
repressed (H3K27me3) histone marks, by low levels of
DNA methylation and low transcription [26]. This chro-
matin state is termed ‘bivalent’, and during differentia-
tion this state is resolved into active (H3K4me3) or
inactive (H3K27me3) marks, leading to higher levels of
active transcription or to gene silencing, respectively.
During malignant transformation, the active state of
differentiation-related promoter genes can be reverted
to bivalent or even hypermethylated at CpG islands to
achieve a permanent silenced state [27]; indeed, DNA-
methylation constitutes a tighter mode of gene silencing
than bivalency or H3K27me3 occupation. Moreover, pro-
moters of developmental regulator genes, which are char-
acterized by bivalent domains in embryonic or adult stem/
progenitor cells, have the highest probability to be found
DNA-hypermathylated in cancer [28]. This is a relevant
difference between normal and cancer (stem) cells: the
inability to actively transcribe those genes prevents can-
cer cells from reaching a terminally differentiated state,
leaving them in an intermediate and phenotypically
plastic state (Figure 1). On the other hand, genes re-
pressed in differentiated cells can revert to a bivalent
state in cancer cells and this bivalency could underlie the
phenotypic plasticity of cancer cell subpopulations, as
reported by Chaffer et al. [29]. In particular, the authors
identified ZEB1 as a key mediator of spontaneous
CD44low (non-CSCs) to CD44high (CSCs) conversion,
acting through repression of the MIR200 family of micro-
RNAs, and noted that the promoter of ZEB1 in CD44high
cells display a chromatin methylation pattern associated
with active transcription (H3K4me3 and H3K79me2
marks), while in CD44low cells it maintains a bivalent
chromatin configuration and is transcribed weakly
(H3K4me3 and H3K27me3 marks) [29].
Rheinbay et al. examined the epigenetic landscape of
Glioblastoma Multiforme (GBM) CSCs, and compared it
with those of normal human astrocytes (NHAs) [30].
Interestingly, a major feature distinguishing CSCs in
GBM from normal cells lies in a lack of the repressive
H3K27me3 mark from promoters normally repressed or
bivalent in NHAs: this results in deregulation of several
transcription factor networks and in an altered WNT
signaling, essential for CSC maintenance and tumor
initiation. These findings suggest a critical role for
Polycomb complexes (responsible for deposition of
H3K27me3) and their regulation for the establishment
and maintenance of the CSC phenotype [31].
In the context of hematopoietic malignancies, we per-
formed a bioinformatic analysis of the available datasets
of LSC-enriched c-kit+ versus non-LSCs c-kit AML
cells from one study discussed above [10]. We found
a significant fraction of genes in c-Kit+/LSC cells charac-
terized by the bivalent mark (N = 2261), and noticed that
the majority of them (>80%) undergo changes in their
chromatin state upon transition to a non/LSC, c-kit
phenotype (Figure 2a). We divided therefore genes that
present the bivalent mark in c-Kit+ or in c-Kit cells into
four distinct classes, based on their epigenetic switching
during the c-Kit+/c-Kit transition (Figure 2b–e). Class 1
(bivalent marks in LSC that lose H3K4me3 methylation
and maintain the repressive H3K27me3 mark in non-
LSC) is the most represented and, as expected, contains
several genes related to pluripotency and strictly involved
in cancer (e.g. Wnt, Notch, Tgf-b, Id2, Zeb1, Axin1, Gli).
Examples of class 2 (bivalent in LSC, and maintaining the
H3K4me3 active mark in non-LSC) and class 3 genes
(presenting only H3K27me3 in LSC, and becoming bi-
valent in non-LSC), which show a more repressive chro-
matin state in LSC than in non-LSC, are: Ip3r, required
for active proliferation [32], Ptp genes [33], genes in-
volved in retinoic acid driven differentiation (Pka and
Rara), and genes controlling adipogenesis/metabolism
(such as Pparg, Bmal1, Clock, S6k1) that potentially outline
the metabolic circuitry responsible for differences in
bioenergetics between CSCs and non-CSCs. Finally,
class 4 (genes marked by H3K4me3 in LSC, found
bivalent in non-LSC), comprehends genes involved in
the CSC phenotype, such as Mpo, Pi3k [34], Vegf, impor-
tant for self-renewal, survival and HSC niche mainte-
nance [35] and Smad genes, which are component of Tgf-b
signaling, hypothesized to be a cardinal regulator of HSC
quiescence, maintaining a slow cycling state in HSCs
[36]. These observations suggest a critical role for the
molecular machineries responsible for the histone mod-
ifications involved in the bivalent chromatin state
(methyltransferase — including MLL and Polycomb
complexes — and respective demethylase activities) in
imposing the CSC phenotype and governing the CSC to
non-CSC transition, consistent with the available findings
discussed above.
New approaches to dissect tumor
heterogeneity: single-cell epigenomics
Epigenomic studies usually rely on the analysis of large
(millions) to relatively small (thousands) cell fractions.
Given the complexity of the stem cell phenotype in
cancer, and the lack of definitive markers to isolate a
100% pure cancer stem cell fraction, single-cell resolution
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Bivalent domains in normal and cancer cells. In normal stem cells, the presence of H3K4me3, H3K27ac and the absence of DNA methylation at
pluripotency genes make them active, while differentiation-related gene promoters are usually characterized by bivalent chromatin that makes
them poised. During normal differentiation, pluripotency genes are stable silenced by DNA methylation, while bivalent domains resolve into an
active or a repressed chromatin state. Cancer cells show a more variegated pattern of chromatin changes in the transition from CSCs to non-
CSCs (see Figure 2 for a specific case): they might maintain bivalent domains in differentiation-related genes (CSCs) and pluripotency genes
(non-CSCs), or acquire irreversible silencing of differentiation-related genes (and tumor-suppressor genes) by DNA methylation. The presence of
bivalent marks instead of stable repression may contribute significantly to the phenotypic plasticity of tumor cells.
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could help to achieve a better definition of the epigenome
associated with the cancer stem cell phenotype, and even
lead to the identification of better markers.
Jaitin et al. developed an automated massively parallel
RNA single-cell sequencing framework (MARS-Seq) to
dissect in an unsupervised manner cellular heterogeneity
of the hematopoietic system [37], while single-cell ex-
pression profiling of five freshly resected and dissociated
human glioblastomas proved cellular heterogeneity at the
transcriptional level in primary tumors and, regardless of
the dominant cellular subtype, highlighted the presence
in each tumor of stem-like proneural cells [38]. These
and other studies [39] demonstrate the value of single-cell
approaches and further suggest that single-cell epige-
nomics would incredibly increase our knowledge in
cell-to-cell variation of heterogeneous cell populations.
Indeed, recent studies suggest that the analysis of at least
some aspects of the epigenome can be achieved at a single
cell resolution. For DNA methylation, a single-cell ge-
nome-wide bisulfite sequencing method has been shown
to be able to deconvolve mixed cell populations and to
individuate rare cells in heterogeneous populations [40].
Using a different single-cell whole-genome bisulfite se-
quencing protocol (scWGBS), Farlik and colleagues dem-
onstrated that is possible to infer cell-state dynamics
through DNA methylation profiling in three in vitro
models of cellular differentiation and pluripotency [41].
Nucleosome positioning, chromatin accessibility, tran-
scription factor occupancy and gene expression are closely
related [42]. Many methods to interrogate chromatin
conformation have been developed [43]: among these
methods, the assay for transposase-accessible chromatin
(ATAC-Seq) allow simultaneous identification of regions
of open chromatin, nucleosome-bound and nucleosome-
free positions in regulatory elements, and fingerprint of
DNA-binding proteins [44]. Recently, two different pro-
tocols for single-cell ATAC-Seq have been published
[45,46].
Interestingly, recent studies allow the identification and
potential isolation of primitive cancer initiating cells [47].
Analysis of these cells with the techniques outlined
above is technically challenging, but offers fascinating
perspectives  to our understanding of the cancer stem cell
phenotype.
Conclusion and perspectives for cancer
therapy
Though the cancer stem cell concept has been intensive-
ly explored in cancer research for the past 15 years, several
critical aspects remain unresolved. It is not surprising
therefore that a mechanistic analysis of epigenetic altera-
tions underlying the cancer stem cell phenotype suffers
from several limitations, and waits for further studies
(we have highlighted the single-cell analyses as a new
technological advance that may surely lead to advances in
this field).
Another limitation is that, while epigenetic alterations
defining differences among CSC and non-CSC tumor cell
populations are being described, much less clear is how
these differences are being achieved, and what is causing
the dynamic equilibrium between the two states.
Nevertheless, we suggest that it is critical to continue to
explore the epigenome of cancer stem cells, considering
its potential relevance for therapy. As aforementioned,
CSCs and non-CSCs have a different sensitivity to both
cytotoxic and epigenetic drugs. Chronic myeloid leuke-
mia (CML) is one of the best-described examples, being
CML stem cells resistant to Imatinib treatment, in con-
trast to the dramatic sensitivity of bulk CML cells [48].
Acute promyelocytic leukemia (APL) represents another
example, where APL stem cells are less sensitive than
bulk leukemic cells to retinoic acid (RA) differentiation
stimulus and only the combination of RA with other drugs
(arsenic, chemotherapy) is able to eradicate the CSC
compartment [49]. In the same disease, the class I HDAC
inhibitor valproic acid (VPA) acts mainly on the bulk of
tumor cells, showing only a mild effect on CSCs [50].
These examples outline the importance of targeting the
right cellular subpopulations, including CSCs. A thera-
peutic strategy based only on CSCs eradication is unlikely
to succeed: reducing the percentage of CSCs below a
threshold could trigger a massive non-CSC to CSC phe-
notypic switch [51]. Therefore, a rational pharmacological
approach could be a combination of debulking drugs
(chemotherapy, cytotoxic drugs) with CSC targeted ther-
apy, maybe directed to those epigenetic modifiers previ-
ously described (JARID1A, JARID1B, KDM1A). A better
understanding of the epigenetic mechanisms controlling
the stem cell functions of tumor cells will therefore allow
the definition of additional therapeutic approaches: we
surmise that epigenetic drugs will represent a critical
weapon in the arsenal of drugs targeting the CSC phe-
notype.
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